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Chapter 7:  
























Due to their important role in normal cellular physiology, protein kinase activity is tightly 
regulated and their aberrant activation can lead to cancer. Chronic myeloid leukaemia (CML) 
is a blood cancer described by unregulated growth of myeloid cells caused by a fusion protein, 
Bcr-Abl, a constitutively active form of the Abelson tyrosine kinase (Abl). Drug targeting of 
either the ATP binding pocket or allosteric pocket has led to durable therapeutic response, 
however the development of drug resistance still poses a major clinical challenge. Recent 
studies exploring synergistic inhibition as an effective approach, by dual targeting of Bcr-Abl 
using both catalytic and allosteric binding inhibitors.   
This thesis implements the use of advanced computational tools to unravel molecular insights 
to aid in the suppression of the emergence of resistance to Bcr-Abl when Nilotinib and ABL001 
are co-administered to target both the catalytic and allosteric binding site of Bcr-Abl protein, 
respectively. Our studies revealed co-binding induced a stable Bcr-Abl protein structure, 
increased the degree of compactness of binding site residues around Nilotinib and subsequently 
improved the binding affinity of Nilotinib.  
Findings in this thesis further provide an atomistic perspective underlying the developed 
resistance of Nilotinib by point mutation at the catalytic active site only and both catalytic and 
activation loop sites. We also recognized and rationalized the structural interplay of this single 
and double mutation upon co-binding of Nilotinib with the novel inhibitor, ABL001. Our 
findings report the distortion of the overall conformational landscape of Bcr-Abl fusion 
oncoprotein caused by the mutation, resulting in a reduction of binding affinity of Nilotinib 
upon single binding. Interesting, co-administration with ABL001 impacted by the mutation 
results in a more compact and stable protein conformation. Findings reveal a structural 
mechanism by which the novel inhibitor ABL001 stabilizes Bcr-Abl fusion oncoprotein upon 
co-binding with Nilotinib, thus suppressing Nilotinib resistance.  
We also provide vital conformational dynamics and structural mechanisms of the mutant 
enzyme at the catalytic site-ligand interaction and mutant enzyme at both catalytic and 
activation loop ligand interactions which could potentially shift the current therapeutic protocol 
in chronic myeloid leukemia treatment, thus aiding in the design of novel inhibitors with 
improved therapeutic features against the mutant proteins. 
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1.1 Background and Rational 
The information presented in this thesis is geared towards comprehending and giving 
molecular insights into Bcr-Abl fusion protein while unraveling the potential of co-
inhibition as a solution of Nilotinib resistance in chronic myeloid leukemia (CML) 
treatment. One of the main setbacks  associated with the  treatment of CML is the 
occurrence of mutations within the Bcr-Abl kinase domain(Hochhaus et al., 2002; 
Gambacorti-Passerini et al., 2003) , which leads to the ineffectiveness of several potent 
tyrosine kinase inhibitors (Shah et al., 2002; Milojkovic and Apperley, 2009) . Firstly, in 
silico exploration of the conformational properties of the protein followed by investigation 
of the mechanism of either tyrosine kinase or allosteric inhibitor resistance provides 
valuable information in the search for a solution to either tyrosine kinase inhibitor or 
allosteric inhibitor resistance. This insight will provide a rational basis for combination 
therapy using both inhibitors for Bcr-Abl pathway in CML treatment. 
The discovery of Bcr – Abl as a necessity in CML pathogenesis and the essential function 
of ABL tyrosine-kinase interaction in facilitated Bcr – Abl transformation has highlighted 
the Abl receptor an appealing therapy target for CML procedures (Ren, 2005). This has 
resulted in a substantial transformation in the therapeutic landscape of CML with the 
development of tyrosine kinase inhibitors (TKIs) that may potentially inhibit the interaction 
of Bcr-Abl and ATP. This approach has resulted in a 10-year survival rate improvement 
from 20% to 80%- 90% (Huang, Cortes and Kantarjian, 2012; Jabbour and Kantarjian, 
2018). Recently, Wylie et al (2017) reported conclusive experimental proof that both 
catalytic and allosteric site co-administration of Nilotinib and ABL001 suppresses the 
emergence of resistance (Wylie et al., 2017a). Therefore, it is essential to obtain insight 
into the structural basis for future dual inhibition with the accessibility of drugs target 
specific to both allosteric and active sites. This will improve our understanding of the 
efficacy of CML co-administrative therapy. The combined blockade of Bcr-Abl by 
Nilotinib and ABL-001 makes a synergistic impact on Bcr-Abl inducing a  more stable and 
compact protein conformation. The binding energy assessment reveals that the joint effect 
 2 
of the two drugs was substantially higher in comparison to the bonding impacts of each 
drug individually. 
Molecular modeling methods have emerged as close counterparts that complement 
experimental studies in current drug discovery process and have substantially aided in the 
understanding of very complicated biological processes (Chaudhari et al., 2017). Different 
computational tools such as Molecular dynamic simulation and advanced post dynamic 
analysis played an important role in the precise molecularlevel understanding of the 
interaction between drug molecules to targets. In this thesis , MD simulations and enhanced 
post analysis techniques e.g Root Mean Square Deviation (RMSD), Root Mean Square 
Fluctuation (RMSF), Radius of Gyration (RoG), Molecular Mechanics energies combined 
with the Poisson–Boltzmann or Generalized Born and Surface area continuum solvation 
(MM/PBSA and MM/GBSA) based binding free energy analysis were used to recognize 
the detailed molecular impact of single catalytic active site mutation only and catalytic and 
activation loop mutation on  the binding landscape of Nilotinib amidst single and co-
binding with ABL001 and to also unveil the molecular structural and conformations of 
single and co-binding of both Nilotinib and ABL001 on Bcr-Abl oncoprotein . 
1.2 Aim and Objectives 
The primary purpose of this thesis is to identify and characterize the principal target 
proteins of Bcr-Abl and subsequently utilize Computer-Aided Drug Design techniques 
(CADD) to investigate potential small molecule inhibitors against these proteins. 
To accomplish this, the following objectives were outlined:  
1. To explore the structural dynamics and in turn, the Bcr-Abl inhibition mechanism when 
bound to both ATP-competitive inhibitor (Nilotinib) and Allosteric inhibitor 
(ABL001). This will provide insight on the binding mechanism at the ATPase active 
site, thereby helping to develop efficient inhibitors against this Bcr-Abl target.These 




1.1. Performing MD simulation on unbound Bcr-Abl, complex of Bcr-Abl with 
Nilotinib, complex of Bcr-Abl with ABL001, and complex of Bcr-Abl with both 
Nilotinib and ABL001 (Apo, Asciminib, Nilotinib and complex ) 
1.2. Calculating the binding free energy of Nilotinib and ABL001 when each is 
bounded individually and when co-administrated to Bcr-Abl. 
1.3. Characterizing the binding landscape of Bcr-Abl and its structural alteration when 
bound to Nilotinib and ABL001 concurrently. 
1.4. Performing per-residue based decomposition for the active site residues of 
Nilotinib and ABL001. 
2. To investigate the molecular impact of an amino acid mutation in a single active site 
on Bcr-Abl of Nilotinib and the novel allosteric inhibitor ABL001. These objective is 
achieved by: 
2.1. Generating a Bcr-Abl mutant by replacing Thr 334 with leucine at Nilotinib's 
active site with Chimera. 
2.2. Performing MD simulation on the following system: complex of Nilotinib bound 
to Bcr-Abl, complex of Bcr-Abl bound to both Nilotinib and ABL001 (nilotinib, 
dual ). 
2.3. Investigating the stability of the different simulated systems over the simulation 
period. 
2.4. Performing multiple post dynamic analysis to understand the effect of gatekeeper 
T334I mutation on the binding of Nilotinib at the catalytic site. 
 
3. To understand the molecular impact of amino acid mutations at both catalytic active 
site and activation loop site on Bcr-Abl of Nilotinib and the novel allosteric inhibitor 
ABL001. In order to accomplish this: 
3.1. Perform MD simulation on unbound Bcr-Abl, complex of Bcr-Abl with Nilotinib, 
complex of Bcr-Abl with ABL001, and complex of Bcr-Abl with both Nilotinib 
and ABL001 (BA-Apo, BA-Nilotinib, BA-ABL001, and BA-Co-inhibition). 
3.2. Calculate the Nilotinib and ABL001 potential free energy when each is bounded 
individually and when co-administrated to Bcr-Abl. 
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3.3. Characterize the binding landscape of Bcr-Abl and its structural alteration when 
bound to Nilotinib and ABL001 concurrently. 
3.4. Perform per-residue based decomposition for the active site residues of Nilotinib 
and ABL001. 
 
1.3 Novelty and Significance of Study: 
A recent study by Wylie et al (2017) reported conclusive experimental proof that both 
catalytic and allosteric site co-administration of ABL001 at the allosteric, myristoyl pocket 
of the protein and Nilotinib at the catalytic pocket suppresses the emergence of resistance 
(Wylie et al., 2017b). These findings showed that ABL001 was bound in a comparable 
conformation to myristate and led to tumor regression in mice when bound in conjunction 
with Nilotinib. It was important to note that no proof of tumor regrowth was observed even 
after the combination dosage stopped. A phase 1 clinical trial was launched to further 
evaluate the dosage of ABL001 in CML patients (ClinicalTrials.gov identifier: 
NCT02081378) (Wylie et al., 2017b). A crystal structure of the protein in combination 
with both Nilotinib and AB L001 was recorded to further validate the research (PDB code: 
5MO4) (Wylie et al., 2017b). Preliminary findings in patients receiving an increased dose 
of a compound disclosed well-tolerated dose-dependent pharmacokinetics. Other studies 
by Cowan-Jacob (2016) and Schoepfer et al (2018) further illustrated ABL001's potency 
as an allosteric inhibitor against the Bcr-Abl protein in CML(Cowan-Jacob, 2016; 
Schoepfer et al., 2018). On the basis of the above experimental research, we present the 
first account of the structural inhibition mechanism caused by the co-binding of allosteric 
(ABL001) and catalytic (Nilotinib) inhibitors. We will also provide insights into the 
Nilotinib resistance mechanism by unveiling the impact of catalytic active site mutation 
only and both catalytic active site and activation loop mutations on the binding affinity of 
Nilotinib and ABL001 amidst single binding or co-binding. The research conducted in this 
study gives rise to new possibilities for the treatment of resistance in CML and helps to 
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2. Overview of Cancer: 
Despite advances in diagnosis and treatment of cancer, cancer remains the second leading 
cause of death in the western world. It has been shown that cancer can be transmitted within 
or between cells (Dhillon et al., 2007). Cancer is a complicated genetic disease that is 
caused mostly by environmental factors such as food poisoning, water contaminants, 
chemicals, and air pollution (Anand et al., 2008). 
Until recently, standard treatments using endocrine therapy, radiation therapy, 
chemotherapy, and surgery have been the available options for cancer patients. This has 
improved survival in many types of solid tumour, but unfortunately, treatment-associated 
toxicity and emergence of resistance have been the primary cause of mortality and 
morbidity (Abou-Jawde et al., 2003). Therefore, a new and more effective therapy is 
urgently needed to enhance patient outcomes.  
Rapid scientific progress in recent years has enhanced our knowledge of cancer biology 
which has led to the discovery of several novel targets, which results in treatments with 
better efficiency, high selectivity and low toxicity (Singh and Salnikova, 2015). Among 
these novel targets are protein kinases. Protein kinases are a phosphate transferase family 
that is essential for phosphorylation reactions and is considered to be one of the most 
significant groups of post-translational protein changes (Masterson et al., 2012). From a 
pharmacological viewpoint, small molecule inhibitors that are highly selective for protein 
kinases results in the inhibition of kinase functions at any step of cellular development (Dar 
and Shokat, 2011). 
2.1 Protein kinases in cancer  
Protein kinases (PKs) play an important role in controlling several biological processes in 
establishing the correct cell functionality, and constitute nearly 2% of human gene  
(Manning et al., 2002). Protein phosphorylation is a key biochemical hallmark of 
metazoans mediated by transferring a γ-phosphate of ATP and covalently attaching it to 
serine, threonine ,tyrosine or histidine residues belonging to peptide or proteins  (Hunter, 
2012) (Figure 2.1). About a third of all proteins in human cells are phosphorylated by 
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protein kinase (Cohen, 2002b) .A significant change on the structure of the substrate 
protein occurs upon phosphorylation by protein kinases (Johnson and Lewis, 2001; 
Kuriyan and Eisenberg, 2007). This phosphorylation consequentially results in cell 
proliferation, migration and survival (Tarrant and Cole, 2009). Hence, Protein kinases are 
considered as key regulators of cell biology that are monitoring a number of signaling 
pathways which are vital for cell growth and survival. However, the overexpression of 
these kinases have been implicated in the initiation, promotion, progression  as well as the 
reoccurrence of cancer and other diseases such as diabetes, vascular disease, inflammatory, 
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This makes the inhibition or the modulation of protein kinases activity an attractive target 
in the treatment of several diseases especially cancer. Nearly 45 protein kinase inhibitors 
have been approved by US FDA, and thousands of clinical studies targeting kinases are 
ongoing(Kornev and Taylor, 2015; Wu, Nielsen and Clausen, 2015) (Figure 2.2). 
Figure 2.2: FDA approved protein kinase inhibitors (Image prepared by author). 
 
2.2 Classification of protein kinases  
The human genome encodes 518 kinases from which about 90 are tyrosine kinases 
(Manning et al., 2002). The protein kinase family is divided into two types:  cytoplasmic 
tyrosine kinases (CTKs), and transmembrane receptor tyrosine kinases (RTKs) which are 
further grouped into subfamilies based on protein sequence homology. The cytoplasmic 
tyrosine kinase (CTK) consist of 34 known members , all containing non-catalytic domains 
and a catalytic kinase domain (Robinson, Wu and Lin, 2000) (Figure 2.3).  
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Figure 2.3:  Structural organization of cytoplasmic tyrosine kinases (Image prepared by 
author). 
Non-catalytic domain names are the following. SH2/SH3: Src-homology; PH: Pleckstrin 
homology; TH: Tec-homology; F-BAR: Bin-Amphiphysin-Rvs; SAM: Sterile-α-motif; 
CRIB: Cdc42/Rac-interactive-binding-motif; FERM: protein-ezrin-radixin-moesin; 
FAT: focal adhesion- targeting. 
2.2.1 Non-catalytic domain 
Non catalytic domain is of interest because of its high diversity as well as its significant 
role in cellular localization (Kung and Jura, 2016). For instance, non-catalytic domains 
such as SH2 which binds phospho-tyrosines allows spatial regulation and specific binding 
of CTKS to tyrosine-phosphrylated target proteins (Neet and Hunter, 1996). SH3 domains 
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improved SH2-dependent phosphorylation (Pellicena and Miller, 2001). Other non-
catalytic domains such as SAM, and CRIB are implicated in protein-protein interaction 
complexes. For example, the CRIB domain in ACK kinase plays an important role in its 
interaction with the activated form of Cdc42 GTPase to promote cell survival and 
multiplication (Kato-Stankiewicz et al., 2001). While, PH and FERM domains play a 
critical role on the localization of the membrane through binding to phospholipids which 
is significant for protein kinase activation pathways (Leonard and Hurley, 2011). Vihinen 
et al. has shown, the location of plasma membrane in Bruton tyrosine kinase (Btk) protein 
is an important step in B-cell activation, and the mutation of its PH domain can lead to X-
linked agammaglobulinemia (XLA) (Vihinen et al., 1994). 
 
2.2.2 Kinase domain 
Kinase domain is a highly conserved protein kinase domain that spans about 300 amino 
acids and catalyzes the transfer of phosphates to the hydroxyl group of protein substrates 
(Kornev et al., 2006). The structure of the kinase domain can subdivide into two domains 
N and C. The N domain consists of one prominent α helix and five stranded β-sheets. In 
contrast, the C domain is a larger and mostly helical segment (Cox, Radzio-Andzelm and 
Taylor, 1994). ATP interacted with the deep cleft located between these two domains just 
below the conserved glycine-rich loop. An optimal phosphate transfer requires a specific 
sequence of spatial arrangements of several residues located in the αC helix , the catalytic 


























Figure 2.4: Cartoon representation of structural organization of the Abl kinase domain 
(PDB: 1IEP). N- and C- lobes are shown in gray. αC helix is shown in orange. The 
activation loop and the glycine rich loop are shown in red and blue respectively (Image 
prepared by author). 
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2.2.3 Role of cytoplasmic tyrosine kinases in cancer 
Cytoplasmic tyrosine kinase has a  significant role in cellular signaling and deregulation 
by point mutation , translocation, deletions or duplications are usually combined by an 
over-activation that leads  to cancer (Hubbard and Till, 2000; Blume-Jensen and Hunter, 
2001). In 1978, Levinson et al discovered that there is a correlation between Src-family 
kinases (SFKs) and tumor progression of malignancy such as breast, colorectal, prostate or 
lung cancer (Zhang and Yu, 2012) . 
 
2.3 c-Abelson (Abl) kinase: a prototypic cytoplasmic tyrosine kinase 
2.3.1 The Abl kinase family 
c-Abl is a member of the cytoplasmic tyrosine kinase which is localized at several sites in 
the cell including nucleus, cytoplasm, mitochondria and endoplasmic reticulum (Wetzler 
et al., 1993) . c-Abl is the  prototype of a subfamily which includes two members : c-Abl 
(Abl1) and its paralogue Arg (Abl2,Abl related gene)(Sirvent, Benistant and Roche, 2008). 
Members of this family are highly conserved throughout the metazoans and ubiquitously 
expressed. Abl play a significant role in signaling pathways that is critical for cellular 
function such as adhesions, differentiation, division and stress response(Sirvent, Benistant 
and Roche, 2008).  
 
 2.4 Chronic myeloid leukemia and Bcr-Abl fusion protein 
2.4.1 Chronic myeloid leukemia 
Deregulation of Abl activity by mutation are usually combined with diverse pathologies 
such as solid tumors, neurodegenerative diseases, and inflammatory disorders. (Khatri, 
Wang and Pendergast, 2016) The most common Abl- related diseases is the chronic 
myelogenous leukemia (CML) , a form of leukemia represented by the unregulated growth 
of myeloid cells in the bone marrow resulting in sufficient amounts of normal  red blood 


















Figure 2.5: Effect of CML on bone marrow and blood components. (Image adapted from 
(Krause et al., 2015). 
  
CML is present in about 15-25% of all adult leukemia patients(Granatowicz et al., 2015). 
The annual incidence rate of CML is 1 to 2 cases per 100 000 and can occur at any age, 
being most prominent in 60-65 year old (Baccarani et al., 2012) (Figure 2.6). 
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2.4.2 NS3 Protein 
The NS3 protein consists of 618 amino acids and a serine-protease domain at its N-terminal 
and an ATP-driven Helicase domain and RNA triphosphate at its C-terminal. The protein 
is also involved in viral assembly independently of the known enzymatic activity 
mentioned (Lescar et al., 2008). During the ZIKV life cycle, the NS3 protein directly 
interacts with the NS5 polymerase to effectively multiply the viral genome. Studies have 
shown that impairment of either domain on either protein lead to non-infectious production 




Figure 2.6: Incidence of Chronic Myeloid Leukemia, Average Number of New Cases per 
Year and Age-Specific Incidence Rates per 100,000 Population (Prepared by Author). 
 
2.4.2 Bcr-Abl fusion gene: 
The expression of the fusion protein (Bcr-Abl) was formed by the conjugation between the 
Abl1 gene on chromosome 9 with the breakpoint cluster region gene (Bcr) on chromosome 
22  generating ( Philadelphia chromosome (Ph)) (ROWLEY, 1973).  The resulting fusion 
protein is an integral activated form of the Abl kinase (Bcr-Abl form) that enables 













Figure 2.7: Chromosomal translocation that generates the Philadelphia chromosome and 
its Bcr-Abl fusion gene (Prepared by Author). 
 
2.4.3 Bcr-Abl: driver of chronic myeloid leukemia: 
Bcr-Abl p210 is considered as one of the most common type for Bcr-Abl fusion. It contains 
all the c-Abl tyrosine kinase sequence except the N-terminal regions which is replaced by 
Bcr. Absence of N terminal (cap regions ) interferes with the myristoylation of the protein 
and inhabited the release of c-Abl tyrosine kinase  from auto inhibition (McWhirter and 
Wang, 1991) .Abl1 gene can be subdivided into two different splicing transcripts: Abl1a, 
and Abl1b . The 1b splicing variant is myristoylated at the N-terminus (glycine 2) whereas 
the 1a variant is 19 amino acids shorter and are not myristoylated (Renshaw, Capozza and 




















Figure 2.8: Structural organization of c-Abl and Bcr-Abl. On the top, Domain structures 
of Abl kinase and on the bottom, the oncogenic Bcr-Abl kinase. NLS: Nuclear localization 
signal, DBN: DNA binding domain, FBD: F-actin binding domain (Prepared by Author). 
c-Abl tyrosine kinase is implicated in a diverse range of cellular activities ranging from the 
regulation of cell growth, survival, oxidative stress and DNA damage response to actin 
dynamics and cell migration (Van Etten, 1999). The two variants of c-Abl have a modular 
organization like that Src family members.  It is characterized by a core tyrosine kinase 
domain which is preceded by SH2 and SH3 domains. c-Abl is exclusively having last exon 
region along carboxy-terminal extension that is containing a nuclear localization signals 
(NLS) that permit the protein to shuttle between cytoplasm and nucleus (Taagepera et al., 
1998) ,and involves in the interaction with F-actin (Hantschel et al., 2005) . It is also having 
a proline -rich motifs that function as binding sites for SH3 domains of adaptor 
proteins.(Hantschel et al., 2005) . 
 
2.4.4 Auto-inhibition mechanism: 
The tyrosine kinase activity of c-abl is very tightly controlled and c-Abl is mostly inactive 
in cells (Vihinen et al., 1996; Van Etten, 1999). Structural and biochemical studies have 
shown a multiple auto inhibitory mechanisms. The auto inhibition relies on a complex set 
of intramolecular interactions that preserve the kinase in a closed and inactive 
conformation. The myristoyl group in the cap region has an important role in the 
SH2 Kinase domain SH3 FBD DBN NLS 
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autoinhibition of c-Abl 1b (Hantschel et al., 2003). The SH2 domain is formed by a central 
antiparallel sheet flanked by a α-helices on each side. The mystrate can interact deeply into 
the hydrophobic pocket in the kinase C-lobe therefore forcing the SH2 and SH3 domain to 
dock against the kinase lobes and keeping the kinase inactive (Pluk, Dorey and Superti-
















Figure 2.9 : The 3-D crystal structure of the Bcr-Abl protein (PDB code: 2FO0(Nagar et 
al., 2006)). The N-cap, SH3, SH2 and kinase domains are shown in green, orange, blue 
and gray, respectively. The SH2-kinase linker is depicted in red, and the green dashed line 
represented the importance of N cap to the stabilization of the downregulated conformation 
of the kinase upon myristate binding (Image prepared by author). 
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2.5 Inhibition of Bcr-Abl  
Many of the drugs that are present in market bind to the orthostatic pocket at the ATP 
binding pocket in Abl kinase (Bcr-Abl). Based on their molecular mechanism of activity, 
the Bcr-Abl orthostatic inhibitor can be divided into two class, type 1, and type 2 . First 
generation inhibitors interact with the active conformation of the kinase, where the catalytic 
important residues are in the optimal position raised the catalysis, i.e. the DFG in the in 
conformation, and the Activation -loop is opened. On the other side, the type 2 inhibitors 
bind to the in active conformation of the Bcr-Abl. i.e the DFG in the out conformation, and 
the Activation -loop is closed or open conformation(Reddy and Aggarwal, 2012) (Figure 
2.10). 
2.5.1 Targeted therapy and development of resistances 
Imatinib (STI-571 ,or CGP-57148) is the first Bcr-Abl inhibitor which was approved in the 
year  2001 as the drug of choice for the treatment of CML (Zuccotto et al., 2010). Imatinib 
is a type 2 inhibitors with IC50 of  10 nM (Zimmermann et al., 1997) . Nevertheless, the 
extended mutation across the Abl protein, makes this drug poorly or incompletely active 
against certain enzymes. The most common mutation are H395P/R, G250E , 
M351T,F359V, , M244V, F317L, Y253H/F, Q252H, E355G, E255K/V and gatekeeper 
T315I. The second generation of Bcr-Abl inhibitors such as Nilotinib and Dasatinib have 
been approved for the treatment of imatinib –resistant patients with the exception of the 
gate keeper T315I.   (Figure 2.11). Nilotinib (Tasigna, AMN107; Novartis) is a type 2 
inhibitors with IC50 of 38nM.In 2012, FDA has approved Ponatinib as a third generation 
ATP competitive tyrosine kinase inhibitor that is efficiently targets for both Bcr-Abl wild 
type and the Bcr-Abl T315I mutation with IC50=0.37nM,2.0nM respectively (Figure 2.10) 
























Figure 2.10:  (A)  The crystal structure of the Abl kinase domain bound to imatinib (PDB: 
1IEP) (Nagar et al., 2002) shows the important features of the inactive configuration of the 
active site. The ionic interaction between lys 271 and Glu 286 is maintained while the DFG 
(Asp-Phe-Gly) motif is flipped out. The activation loop is folded towards the active site 
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Abl kinase domain crystal structure bind to dasatinib (PDB: 2GQG, (Tokarski et al., 2006) 
, shows significant characteristics of active kinase conformation.  To coordinate the ATP 
phosphate group, the ionic interaction between Lys271 and Glu286 is essential. The 
phosphorylated Tyr393 forms an Arg386 hydrogen bond and helps stabilize the active 
conformation (Image prepared by author) . 
 
Allosteric binding inhibitors have also been found to inhibit the Abl activation, for instance 
, DCC-2036 is switch pocket inhibitor that allosterically binds to the Arg386/Glu282 
residues in the switch regions and hinder Abl from adopting an active conformation(Chan 
et al., 2011). DCC-2036 has been found to overcome most of imatinib mutation including 
T315I mutation. DCC-2036 is now under Phase I clinical trials with T315I mutation CML 
patients, with the study currently awaiting results (Figure 2.11)(Chan et al., 2011).  
Other examples include GNF-2 and GNF-5 which were able to inhibit Bcr-Abl growth with 
the exception of T315I mutation (Webersinke, 2016). Similarly, ABL001 is allosterically 
bound to Bcr-Abl with IC50 = 1-12nM (Schoepfer et al., 2018), recent studies have shown 
that monotherapy using ABL001 which led to tumor regression in mice xenografted with 
KCL22 CML cell line. Unfortunately, the tumors eventually recurred (Figure 2.11) (Wylie 
et al., 2014, 2017; Eadie et al., 2015). 
However, dual targeting of GNF-2 with Nilotinib or ABL001 with Nilotinib have shown a 
highly synergistic effect compared to mono therapeutic treatment, being able to overcome 
gatekeeper T315I mutation. Therefore dual targeting of  both ATP binding r, and allosteric 
inhibitors represents an innovative way to overcome mono therapeutic resistance (Iacob et 
al., 2011) (Wylie et al., 2017). This may be attributed to the effect of GNF5  when bound 
to the myristate pocket stabilizing the in active form of the T315I mutant, and the new state 
enable confirmation where I 315 no longer limits access of Nilotinib to the hydrophobic 
binding pocket . In this case, the  allosteric targeting of Abl can cause dynamic  
perturbations to the ATP binding site residues and this explains the mechanism by which 
synergistic interaction occurs (Zhang et al., 2010) . 
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Recently, Mono bodies shows a highly allosterically inhibition to Bcr-Abl by interfering 
with the SH2-Kinase domain complex. This induces the apoptosis in CML cell lines and 




Figure 2.11:  The 2D structures of some kinase inhibitors.   
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2.6 Clinical Developments of Protein kinase inhibitors: 
Protein kinase inhibitors are rapidly growing in drug discovery, as protein kinases are 
considered as the second most significant group of drug targets after G-protein-coupled 
receptors. They account for about 20–30% of the drug discovery program of many 
companies (Vlahovic and Crawford, 2003)(Cohen, 2002a). Recently, FDA has approved 
49 compounds which have been identified as protein kinase inhibitors (Table 1) . Despite 
these encouraging results, response to these protein kinase inhibitors are surrounded by the 
development of resistance, toxicity ,and efficiency which remains challengeable (Fabbro, 
Cowan-Jacob and Moebitz, 2015) .Furthermore, Accomplishing the selectively of the 
kinase inhibitors for particular protein kinases remain a significant challenge(DAVIES et 
al., 2000; Noble, Endicott and Johnson, 2004). Computational methods can have a key 
effect on Protein kinase inhibitors design and will stand to be an important feature for the 
development of these inhibitors (Ferrè, Palmeri and Helmer-Citterich, 2014), so that , many 
researcher have been motivated to overcome various limitation of kinase inhibition , 











Table 2.1: list of FDA-approved small molecule protein kinase inhibitors.  
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3 Computational Approaches for Biomolecular Structure and Drug Design 
3.1 Introduction 
In the medical world today, there has been a paradigm shift in the design of drugs, novel 
methods of drug design are constantly being exploited in an endeavor to improve efficiency 
and encounter challenges faced during the drug design process (Zheng et al., 2013; 
Ramírez, 2016). Molecular modeling (also known as computational chemistry ) is the 
science and art of studying molecular function structure through model building and 
computing using computational methods to simulate the behavior of molecules 
(Ramachandran, Deepa, and Namboori, 2008). Molecular modeling is a rapidly growing 
discipline of science in the research community. In the medical domain, molecular 
modeling is the mainstream of drug design and discovery. It entails the use of algorithms 
to carry out calculation, data processing, and automated reasoning tasks to elucidate 
chemical properties problems(Young, 2001). Simulations use an equation that elucidate 
the behaviour of matter on an atomic level to analyse structural properties of molecules 
such as gases, liquid, solids to predict and explain chemical phenomena. (Young, 2001; 
Jensen, 2002; Leszczynski, 2012). It gives a platform for scientists to expect chemical 
reactions using computer software so that saving time, and experimental costs (Montoya, 
Mondragón and Truong, 2002; Bajorath, 2012; Rohland and Reich, 2012). 
Molecular modeling covers a wide range of topics including quantum chemistry, molecular 
mechanics and molecular dynamics (Lewars, 2011). There are two fundamental molecular 
modeling principle that are used to establish the energetics and conformational changes to 
the drug-target system (Figure 3.1): 
1) Quantum Mechanics 















Figure 3.1: The scientific domains in which Applications of Quantum and Molecular 
Mechanics fit into (Prepared by Author).   
In this chapter, quantum mechanics, molecular mechanics and molecular dynamics 
simulations will be explained on, to get more insight into the rationale behind the chosen 
energy descriptors for this study. The principle behind each of the computational tools 
employed in the study will also be further explained 
 
3.2 The Principle of Quantum Mechanics 
Quantum mechanics (also known as Quantum physics or Quantum field theory) is one of 
the most successful branches of classical physics in the history of science. It identifies the 
characteristic behavior of matter and energy at molecular, atomic, nuclear and smaller 
microscopic levels (Griffiths, 2005; Zettili, 2009). The principle of quantum Mechanics 
hypothesis was suggested by Max Planck in the early 20th century in 1900 (Bose, 1924). It 
states that any energy-radiating atomic system can be theoretically split into a number of 
different energy components so that each of the energy elements is equivalent to the 
 44 
frequency with which each of them radiates separately (Müller, 2008).  In biological 
process, QM plays a significant role in understanding this process at the molecular level 
such as bond forming /breaking atomic transfer and electron excitation.  
Planck theorized that energy was transferred in portions called quanta, hence the name 
quantum hypothesis. It is illustrated by the equation below: 
E=hv     (Eq 3.2.1) 
where E is energy, h is Planck's constant, equal to 6.626068 × 10−34 Joule-second (J-s) and 
the Greek letter v is the photon’s frequency (Hull, Tessner and Diamond Jr., 1978; 
Mittelstaedt, 2008; Quincey, 2013). 
The quantum phenomena can be best clarified by the Copenhagen interpretation. Danish 
physicist Niels Bohr and German physicist Werner Heisenberg approached a set of 
statements which attempt to clarify how QM explains our understanding of nature (Stapp, 
1972). It stated that physical systems normally do not have certain properties prior to being 
measured, and quantum mechanics can only expect the probabilities that measurements 
will produce certain results (Hanson, 1959; Kober, 2009; Hollowood, 2013). 
Despite there were many challenges to the Copenhagen interpretation, but it still remains 
the frequently taught explanations of quantum mechanics(Zinkernagel, 2011).The quantum 
hypothesis laid a foundation for many physicists like Albert Einstein, Niels Bohr, Werner 
Heisenberg, Erwin Schrödinger, and many others to further develop the field of quantum 
physics (Zettili, 2009; D’Espagnat, 2011).  
 
3.2.1 The Schrödinger Wave Function 
In January 1926, the atom's quantum mechanical model was suggested by Austrian 
biologist Erwin Schrödinger. Expanding on the Bohr atom template, which suggests that 
atoms are placed around a core in concentrated linear positions, Schrödinger used 
mathematical formulas to define the likelihood of placing an electron on a precise route. 
The model is depicted as a nucleus encircled by an elevated and small density electron 
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cloud (Dronamraju, 1999; Leach, 2001; Atkins and Friedman, 2011) (Figure 3.2).  
According to quantum mechanics, all particles are termed as a wave function with no 
defined position or momentum until they are detected. The probability of each possible 
observation may be determined by the wave function(Leach, 2001; Atkins and Friedman, 
2011). 
Schrödinger found that by adding the properties of an atom, being the mass and charge, to 
the equation, he was able to predict a series of shapes showing the wave pattern of electrons 









Figure 3.2: The Bohr Model demonstrated the atom to have a positively charged nucleus 
that was orbited by negatively charged electrons. This model was corrected by the equation, 
which evidenced electrons to have wave functions dependent on mass and charge of the 
atom. The two models are the fundamentals of what we now know as Quantum mechanics 
(Prepared by Author). 
In its simplest form, the Schrödinger wave equation(Laskin, 2002) may be represented as: 
𝐇𝛙 = 𝐄𝛙                                                     (Eq 3.2.2) 
Where, Η is called Hamiltonian operator (contains derivatives with respect to atom 
location), Ψ is the wave function and E, is the energy of the system also referred to as the 
Schrödinger's Model (1926) 
Ground state 
1st energy level  
2nd energy level   
3rd energy level   
Nucleus 
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operator energy eigenvalue(Jensen, 2007; Lewars, 2011).This description is a probabilistic 
description of electron location but can't predicate their precise location so that in order to 
get a disclose physical model of Schrödinger’s equation, the wave function must be 
continuous, single-valued and antisymmetric relative to electrons interchange(Young, 
2001). The molecular Hamiltonian operator is derived from the sum of the atom’s total 
potential energy (V) and the kinetic energy (T) represented as 
 𝐇 = 𝐓 + 𝐕                                                   (Eq 3.2.3) 
When considering particles as point masses, and neglecting relativistic effects, the 
Hamiltonian will, therefore, constitute all the kinetic and potential energy operators for all 
the electrons and nuclei in a molecule.  
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3.2.2 The Born- Oppenheimer Approximation Theory 
In 1927, Max Born and J. Robert Oppenheimer proposed the Born-Oppenheimer 
approximation theory (Born and Oppenheimer, 1927). This theory assumes that the motion 
of atomic nuclei and electrons in a molecule can be separated. In mathematical 
terminology, it allows the wave function of a molecule to broken into its electronic and 
nuclear components. Electrons are considered to be of lighter weight than the nuclei. This 
leads to the electrons having a greater velocity and moving instantaneously to nuclei 
movement. The distribution of electrons within a molecule is therefore defined by the 
location of the nuclei (Bludman and Daitch, 1954; Woolley and Sutcliffe, 1977; Wudka, 
1990; Matsika, 2010). 
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The disparity in velocities of the nuclei and electrons allow the application of the Born-
Oppenheimer approximation, thus minimizing the complexity of the wave function of the 
Hamiltonian equation.  
The simplified wave function is as follows: 
𝛙(𝐫𝐞𝐥𝐞𝐜) =  𝛙(𝐫𝐞𝐥𝐞𝐜) (𝛙(𝐫𝐧𝐮𝐜𝐥)                  (Eq 3.2.5) 
Eq 3.2.2 is converted: 
𝑯𝑬𝑵𝛙(𝐫𝐞𝐥𝐞𝐜) =  𝑬𝑬𝑵𝛙(𝐫𝐞𝐥𝐞𝐜)                        (Eq 3.2.6)  
Where H EN denotes a difference between terms based activity to fixed nuclear positions 
(VNN) or their activity to the non-fixed electron positions. Eq. 3.2.5 shows EEN, which is 
derived from the sources being the fluctuating electron co-ordinates and fixed nuclear co-
ordinates.  
(𝐇𝐞𝐥 + 𝐕𝐍𝐍) 𝛙(𝐫𝐞𝐥) =  𝐄𝐄𝐍𝛙(𝐫𝐞𝐥)               (Eq 3.2.7) 
Electronic motion is best described by the electronic Schrödinger equation. This 
approximation is more accurate when it is applied to ground electronic states. (Deslauriers, 
2011; Beringer and Others, 2014). 
 
3.2.3 Potential Energy Surface  
The potential energy surface is an effective mathematical representation between 
molecular vibrational motions of a molecule, along with its geometry and its nuclear 
probability distribution by finding solutions to the time-dependent Schrödinger equation. 
This concept is birthed from the Born-Oppenheimer approximation elucidated above, 
where electrons differ according to the positional states of the nuclei in a manner such that 
the potential energy surface is taken as the potential of atoms to collide with each other in 
a molecule (Woolley, 1991; Atkins and Friedman, 2011). A potential energy surface 
displays high potential energy regions, indicating high-energy nuclear arrangements or 
molecular conformations and low energy regions indicating low nuclear energy 
conformations. The potential energy surface is utilized in computational chemistry to 
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analyze the lowest energy state and the positional geometry of a molecule at this state 











Figure 3.3: graphical representation of a two-dimensional potential energy surface (PES) 
(Adapted from The California State University 2017). 
 
3.3 The Principle of Molecular Mechanics  
Molecular mechanics (MM) or force-field methods is a technique that is used to predict the 
energy of a molecule as a function of its conformation. This involves predictions of 
equilibrium geometries, transition states, and relative energies between conformers or 
between different molecules (Shattuck, 2003; Vanommeslaeghe et al., 2014). 
Molecular mechanics is a computational method that computes the potential energy surface 
for a specific order of atoms by the use of potential functions that are obtained by using 
classical physics (Tsai, 2002; Bowen and Allinger, 2007).  
It depends on the following assumptions: 
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1) Electrons are treated around a nucleus that is a perfect sphere. 
2) The molecular bonds are regarded as springs. 
3) Potential features are dependent on experimental parameters such as force constants 
and equilibrium values. 
4) the potential energy function is the total functions for bond stretching, angle 
bending, torsional energies, and non-bonding interactions. 
Molecular mechanics requires less computing cost than QM methods. It is however 
restricted by certain parameters of equations such as the different force-field for different 
types of atoms. Moreover, it is inapplicable for electronic properties (Hu, Elstner and 
Hermans, 2003; Wallrapp and Guallar, 2011). 
 
Molecular mechanics can be useful for large molecules such as proteins so that its mainly 
used in the molecular dynamics field (Marques and Brown, 2002; Cournia, Smith and 
Ullmann, 2005). 
 
3.3.1 Potential Energy Function 
In the force field, all atoms are known as building block whereas electrons are not 
considered as single entities. This implies that rather than finding solutions to the 
Schrödinger equation, explicit bonding information must be specified (González, 2011). In 
the force field, molecules are described by a “ball and spring” analogy, with atoms of 
different sizes and different bond length. It was founded that different molecules might 
have structural similarity due to the atoms they are made up of. The notion atom types were 
then coined and are dependent on the atomic number and chemical bonding fixating it in 
place (Jensen, 2007)(Guest and Sherwood, 2002). 
The potential energy function (PEF) force field of a molecular system may be assembled 
in terms of a set of force field energy equations that are solely based on Newtonian classical 
physics. These equations calculate the energy of the system as well as the atom types that 
construct the molecule (Huang et al., 2010). 
 50 
The following equations best describe the sum of all individual molecular components that 
make up the total potential energy: 
1. Bond stretching (between directly bonded atoms) 
 𝐄𝐫 =  ∑𝐊𝐫(𝐫 − 𝐫𝟎)
𝟐                                                              (Eq 3.3.1) 
 
2. Angle bending (atoms bounded to same central atoms) 
𝐄𝛉 =  ∑𝐊𝛉(𝛉 − 𝛉𝟎)
𝟐                                                              (Eq 3.3.2) 
3. Bond torsion 
𝐄𝛟 =  ∑𝐊𝛟[𝟏 + 𝐜𝐨𝐬(𝐧𝛟 − 𝛟𝟎)]                                                 (Eq 3.3.3)         
4. Non-bonded interactions (van der Waals and electrostatic) 
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 )]             (Eq 3.3.4) 
Where: Kr, Kθ, Kϕ are force constants for a bond, angle, and dihedral angle and ro, θo, ϕo 
are the equilibrium distance, angle, and phase angle. Parameter rij is distance, while Aij and 
Bij are van der Waal parameters. D is the molecular dielectric constant; qi and qj are charge 
points. 
The final potential energy function equation is, therefore: 
𝑬𝒕𝒐𝒕𝒂𝒍 =  𝑬𝒓 + 𝑬𝜽 + 𝑬∅ + 𝑬𝒏𝒃             (𝐸𝑞 3.3.4)     
Where, 𝑬𝒕𝒐𝒕𝒂𝒍   donate total energy, 𝑬𝒓  denote bond-stretching energy, 𝑬∅  donate angle-
bending energy, 𝑬∅  donate bond rotation energy, and 𝐄𝐧𝐛  donate non-bonded 










Figure 3.4: Diagrammatic representation of bonded and non-bonded interactions acting in 
molecular motion (Prepared by Author). 
 
3.4 Quantum Mechanics/Molecular Mechanics (QM/MM) 
To decline negative implications associated with using Quantum Mechanics (QM) and 
Molecular Mechanics (MM) approaches so that computational chemists have established 
combinational QM/MM algorithms, which merge QM  descriptors with the low-cost 
computing rate of MM (Levitt, 1976; Shurki and Warshel, 2003; Adcock and McCammon, 
2006a) (Figure 3.5).  QM/MM methods employ algorithm that combined the description 
accuracy of QM and the low computational cost of MM (Sauer and Sierka, 2000; Senn and 
Thiel, 2009; Lu et al., 2016). The technique of QM/MM involves two step-wise domains. 
The reactive domain defined by QM, whereas, the non-reactive domain treated with MM 
(Bornemann, Nettesheim and Schütte, 1998).  Although  QM calculations are very precise 
at describing the electronic structure of molecular systems, it is highly computationally 
expensive and time-consuming (Honarparvar et al., 2014).so that hybrid QM/MM  propose 
to accurately describe quantum mechanics with the low cost applied to molecular 
mechanics. 
Amongst the notable advantages of hybrid QM/MM method over QM and MM, that QM 
or MM may not be appropriate for every structure-based drug design study; therefore, 
further investigation of the technique may be required(Lu et al., 2016), so that hybrid 










Figure 3.5: A schematic representation of a hybrid QM/MM/MD model (Prepared by 
Author). 
3.5 Force Field 
In 1970s the first Molecular Mechanics (MM) force field was formulated (González, 2011). 
A force field is a mathematical function with a delineated set of parameters. These 
parameters describe the molecular energy systems to specific particle coordinates (Kang, 
Liu and Guo, 2014). Commonly used biomolecular force fields include AMBER (Wang et 
al., 2005), CHARMM (Brooks et al., 2009), NAMD (Phillips et al., 2005), GROMOS 
(Christen et al., 2005) and OPLS-AA(Guvench and MacKerell, 2008). All force field 
parameters are obtained from either experimental data sources, ab initio or semi-empirical 
QM (González, 2011). Force field functions are assumed to be wholly dependent on atomic 
orientations. They have been used as representatives for describing potential energy surface 
for different types of molecular systems with varying degrees of freedom (Ponder and 
Case, 2003). This force field function is used to understand the specific forces acting within 
the molecular system. In this thesis, the AMBER14 force field was implemented to 
characterize the Bcr-Abl protein, whilst GAFF was used to interpret the ABL001 and 
Nilotinib ligands (Halgren and Damm, 2001). The AMBER14 force field provides a 
favorable balance in energy between the helical and extended regions of the peptide and 
protein backbones with improved dihedral torsions (Wang et al., 2004). 
 




  3.6 The principle of Molecular Dynamics  
Over the year’s crystallographic studies, Nuclear Magnetic Resonance Spectroscopy 
(NMR), and biological assays have been engaged to credibly determine the crucial role of 
protein flexibility in ligand binding and to provide insights into the biomolecular structures 
(Nair and Miners,2014). In late 1950, Molecular dynamic first emerged were Alder, 
Wainwright, and Rahman established simulation methods for the dynamics of liquids. The 
computational chemistry domain has developed since then and from the early 1970s, 
molecular dynamics has become the most widely used method to study structure and 
dynamics of macromolecules such as DNA or protein (Tsai, 2002).There are two common 
types of simulation techniques classical MD, and Monto Carlo method(Adcock and 
McCammon, 2006b). Monto Carlo method depends on the prospects by creating a large 
number of conformation and transition from one state to the other in a specific statistical 
manner (Earl and Deem, 2008).  On the other hand, classical MD simulation, trajectories 
of atoms and molecules are created by mathematically solving Newton’s equation of 
motion for a system of interacting particles, in which forces between the particles and 
potential energy are defined by molecular mechanics force fields(Cornell et al., 1995). 
Recently, there are many hybrid techniques have also been released. One of the main 
advantages of MD over MC is its capacity to allow for dynamical properties of a system 
such as rheological properties and time-dependent responses(Nair and Miners, 2014). 
Molecular dynamics is especially valuable in biochemistry and molecular biology as it 
affords the occasion to identify and categorizes on an atomic scale that may impact the 
biological properties of a system (Jarosaw Meller, 2001). 
In MD, complex systems are modeled at atomic level and Newton’s equations of motion 
are mathematically solved to indicate the time of evolution of a specific system, allowing 
a derivation of its kinetic energy and thermodynamic properties through the application of 




Figure 3.6: Basic algorithm of Molecular Dynamics. Where Epot = potential energy; t = 
simulation time; dt = iteration time; x = tom co-ordinates; F = force component; a = 
acceleration; m = atom mass and v = velocity (Image adapted from (Hospital et al., 2015). 
The overall purpose of this computational technique is to utilize Newton’s equations to 
solve and understand the energies and structural dynamics of a molecular network system. 
The following initial particle conditions are required: 
1. Positions and velocities of each particle 
2. A good force field to characterize the forces between atoms, e.g. AMBER or CHARMM 
3. Boundary conditions that need to be engaged 
Atomic trajectories are generated through the integration of Newton’s equations of motion 
for atoms on an energy surface.  
The classical equation of motion may then be solved:  
𝐅𝐢 =  𝐦𝐢
𝐝𝟐𝐫𝐢(𝐭)
𝐝𝐭𝟐
                                                      (Eq 3.4.1) 
 
Where ri (t) is the particle position vector, t is time-evolution, m is the mass of the particle 
and Fi depicts the interacting force on the particle.  
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Molecular dynamics can be categorized into 4 continuous technical steps that are repeated 
numerously to generate a trajectory (Figure 3.7).   
 
Figure 3.7. The cycle of molecular dynamics steps (Prepared by Author). 
The steps are outlined below: 
1) The fundamental requirements of the biomolecular system are defined: 
 The coordinates of each atom  
 The bond characteristics between each atom 
 The acceleration of atoms 
 
2) Each atom’s potential energy is computed. 
3) The energies from the step are then utilized to solve the equation of motion. 
4) The new state of the system needs to be saved, and the atoms’ co-ordinates changed, 
and step forward in the simulation taken. The cycle then restarts from step 1.  
 
Once the trajectory is fully generated, quantitative analysis of the system’s time- evolution 
can proceed.  
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3.6.1 Molecular Dynamics Post-Analysis 
Molecular dynamics trajectories are created from the production run of the simulation. The 
trajectories can be defined as sequential snapshots that are characterized by both positional 
co-ordinates and velocity vectors and detail the time evolution of the system in phase space 
(Jarosaw Meller, 2001; Likhachev, Balabaev and Galzitskaya, 2016).   
When choosing analytical software, three requirements are essential: 
1. Qualitative visualization software that will not only display the trajectory’s video 
clips but also generates high-quality snapshots/images. 
2. The software should have prompt processors that will accommodate large volumes 
of data. 
3. A variety of analysis options should be available on one program.  
 
The selected post-dynamic techniques and calculations should be dependent on the nature 
of the MD study; however, critical quantitative evaluation is necessary to support any 
visual systemization. 
For the purpose of this study, the post dynamic analysis of the trajectories is critical to 
determining the:  
1. energetic and conformational stability of the biomolecular system.  
2. The characteristics of the system’s small molecule binding landscape and the 
thermodynamic energy fluctuations along the system’s clustered trajectory. 
3. dynamic conformational features or variability of the biomolecular system. 
 
3.6.1.1 System Stability 
Convergence: 
Convergence is an empirical description of protein dynamics. It specifically describes 
protein dynamics based on bond types and bond angle vibrations during the unfolding of a 
protein. This fusion toward equilibrium and portrayal of a conclusive plateau is impertinent 
 57 
for an MD trajectory to be accurate and reproducible. At this plateau, the protein-ligand 
system displays energetically stable conformations (Galindo-Murillo, Roe and Cheatham, 
2015). 
Root Mean Square Deviation (RMSD): 
Spatial difference between two static structures of the same trajectory measures the 
deviation of a complex (Brüschweiler, 2003). The RMSD of a trajectory is defined as: 
𝐑𝐌𝐒𝐃 =  (






                                (Eq 3.4.2) 
 
Root Mean Square Fluctuation (RMSF): 
The root mean fluctuation (RMSF) of a protein measures residue’s Cα atom fluctuations is 
based on the average protein structure along the system’s trajectory. The RMSF captures 
the fluctuation for each atom around its average position (Martínez, 2015; Margreitter and 
Oostenbrink, 2017). It is calculated using the equation below: 
𝐬𝐑𝐌𝐒𝐅 =  
(𝐑𝐌𝐒𝐅𝐢 − 𝐑𝐌𝐒𝐅)
𝛔 (𝐑𝐌𝐒𝐅)
                                         (Eq 3.4.3) 
 
Where: RMSFi is the RMSF of the i
th residue, from which the average RMSF is subtracted. 
This is then divided by the RMSF’s standard deviation to yield the resultant standardized 
RMSF.  
Radius of Gyration (RoG): 
The radius of gyration in a protein can be calculated as the root mean square distance of 
the atoms from their common centroid/centre of gravity(Lobanov, Bogatyreva and 
Galzitskaya, 2008). This allows for the estimation of compactness of a protein complex 
along a trajectory(Huang and Paul, 2007; Pan and Patterson, 2013). RoG can determine 
how folded or unfolded a biomolecule over a given simulation period(Lobanov, 
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Bogatyreva and Galzitskaya, 2008), in addition, the overall stability of biomolecular 
structure over a given period can be determined from RoG calculation  
Mathematically, RoG is calculated as follows; 
𝒓𝟐𝐠𝐲𝐫 =  (
  ∑ 𝒘𝒊𝒏𝒊−𝟏 (𝒓𝒊 − 𝒓
−)?̇?
∑ 𝒘𝒊𝒏𝒊−𝟏
)                              (Eq 3.4.9) 
Where ri represents the position of the atom i
th atom whiles r is the center weight of atom 
i. 
The average RoG is calculated by taking the average over the number of frames in a 
trajectory (Lobanov, Bogatyreva and Galzitskaia, no date). 
Solvent Accessible Surface Area (SASA) 
The solvent-accessible surface area (SASA), is a derivative of the area over which absolute 
contact between the proteins’ Van der Waals surface and the solvent arises. This feature 
gives information relative to the compactness of the structure as well as the magnitude of 
hydrophobicity in the interior of the folded protein which is important for biomolecular 
stability (Richmond, 1984). 
 
3.6.1.2 Thermodynamic Energy Calculations  
Calculations of binding energy are crucial in computational chemistry studies as they are 
the endpoint method that accounts for the ligand-receptor interactions. Approximations of 
binding free energy lead to the development of various algorithms including energy 
perturbations, thermodynamic integration, molecular docking calculations, etc  (Vakal, 
2017).  
The Molecular Mechanics/Generalized Born Surface Area method (MM/GBSA) methods 
have been regarded as the most accurate and efficient method in estimating binding free 
energies for biological macromolecules (Homeyer and Gohlke, 2012). The free binding 
energy computed by these methods for a protein system which comprises of the complex, 
ligand and receptor can be represented as: 
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∆𝐆𝐛𝐢𝐧𝐝 = 𝐆𝐜𝐨𝐦𝐩𝐥𝐞𝐱 − 𝐆𝐫𝐞𝐜𝐞𝐩𝐭𝐨𝐫 − 𝐆𝐥𝐢𝐠𝐚𝐧𝐝                                 (Eq 3.4.4) 
∆𝐆𝐛𝐢𝐧𝐝 = 𝐄𝐠𝐚𝐬 + 𝐆𝐬𝐨𝐥 − 𝐓𝐒                                                          (Eq 3.4.5) 
𝐄𝐠𝐚𝐬 = 𝐄𝐢𝐧𝐭 + 𝐄𝐯𝐝𝐰 + 𝐄𝐞𝐥𝐞                                                           (Eq 3.4.6) 
𝐆𝐬𝐨𝐥 = 𝐆𝐆𝐁/𝐏𝐁 + 𝐆𝐒𝐀                                                                     (Eq 3.4.7) 
𝐆𝐒𝐀 = 𝛄𝐒𝐀𝐒𝐀                                                                                   (Eq 3.4.8) 
 
Here, Egas symbolizes gas-phase energy consisting the internal energy Eint; Coulomb 
energy Eele and the van der Waals energy Evdw. The Egas was calculated from the FF14SB. 
Gsol is the solvation free energy that was computed from the polar states, non-polar states, 
and GGB/PB energy contribution. GSA is the non-polar solvation energy. GSA was calculated 
from the solvent accessible surface area (SASA) by utilizing a water probe radius of 1.4 Å, 
while the polar solvation GGB/PB involvement was calculated by solving the equation of 
GB/PB (Rastelli et al., 2010; Genheden and Ryde, 2015).T and S signifies the total entropy 
of the temperature and solute respectively. The MM/GBS and MM/PBSA algorithms 
propose quantifiable analysis of the binding affinity of the inhibitor to the protein and thus 
enables to explain molecular docked structures.  
 
 3.7 Other Molecular Modeling Tools Used in this Study 
3.7.1 Molecular Docking 
Molecular docking has become a fundamental tool in the drug discovery industry. It 
employs multiple methods to predict the binding affinity and configuration of a complex. 
Most general use of docking is in ligand-receptor complexes, although other uses are 
documented. There are two major steps in docking: 
1. Sample conformations of a ligand in the active site of the protein. 
Different algorithms may be used when sampling the numerous conformations of 
the docked complex. This can be the “lock and key” model which describes the 
 60 
ligand and receptor as rigid structures, or the ligand may reflect flexibility by 
random or simulation-based methods. The latter algorithm is the frequently used 
method as it permits a more realistic fit of the ligand to the protein (Morris and 
Lim-Wilby, 2008).  
2. Ranking the different conformations by scoring function. 
 The scoring function may be based on statistically preferred contacts, MM force 
fields or pre-existing protein-ligand binding affinities (Morris and Lim-Wilby, 
2008). 
 
Molecular docking comes with many inconsistencies (Chen, 2015). Docked compounds 
are often criticized due to incorrect binding sites or choice of docked complex (Ferreira et 
al., 2015). Due to this inconsistencies issues, all docked complexes in this study were 
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Background: Aberrant and proliferative expression of the oncogene Bcr-Abl in bone 
marrow cells is one of the prime causes of chronic myeloid leukemia (CML). It has been 
established that the tyrosine kinase domain of the Bcr-Abl protein is a potential therapeutic 
target for the treatment of CML. Although first and second line inhibitors against the 
enzyme are available, recent studies have indicated that monotherapeutic resistance has 
become an aggrieved challenge.  
Objective: In recent studies, the dual inhibition of Bcr-Abl by Nilotinib and Asciminib 
was shown to overcome drug resistance. This prompted us to investigate the dynamic 
behind this novel drug combination. 
Methods: By the utilization of a wide range of computational tools, we define and compare 
Bcr-Abl’s structural and dynamic characteristics when bound as a dual inhibitor system. 
Results: Conformational ensemble analysis presented a sustained inactive protein, as the 
activation loop, inclusive of the characteristic Tyr257, remained in an open position due to 
the unassailable binding of Asciminib at the allosteric site. Nilotinib also indicated more 
propitious binding at the catalytic site in the presence of Asciminib, thus exposing new 
avenues in treating Nilotinib-resistance. This was in countenance with intermolecular 
hydrogen bond interactions with key binding site residues GLU399, Asn259 and Thr252.  
Conclusion: The investigations carried out in this study give rise to new possibilities in 
the treatment of resistance in CML, as well as assisting in the design of novel and selective 








4.1 Introduction  
Chronic myelogenous or myeloid leukemia (CML) is a cancer of white blood cells 
(WBCs), distinguished by an increase in leukemic blasts (white cells), also called 
granulocytes. As the CML matures, the granulocytes leak out of the bone marrow and 
circulate through the bloodstream, thus leading to a shortage of red blood cells and 
platelets, causing anemia, bruising and/or bleeding 1,2. CML is present in about 15-25% of 
all adult leukemia 2, with an annual incidence rate of 1 to 2 cases per 100 000 3. Being 
Philadelphia chromosome positive, CML is characterized by a translocation between 
chromosome 9 and 22, thus leading to an alteration in the breakpoint cluster region (Bcr) 
and allowing for the formation of the Bcr-Abl gene 4. A breakpoint in BCR leads to the 
formation of a fusion protein 5,6, which results in the phosphorylation of the Bcr-Abl  
protein 7,8. This phosphorylated Bcr-Abl protein leads to deregulated tyrosine kinase 
activity, a characteristic feature of CML 9-10. 
 
The Bcr-Abl protein is formed from two portions: first, the N-Terminal that comprises of 
the SH2 and SH3 domains and N-Terminal cap that plays a significant role in the regulation 
of kinase activity and secondly, the C-terminal which is composed of an array of signaling 
and recognition domains that are involved in many cellular functions, including a DNA-




Figure 4.1: The 3-D crystal structure of the Bcr-Abl protein (PDB code: 1OPK). The SH3, 
SH2 and kinase domains are shown in green, yellow and red, respectively. The SH3-SH2 
connector is depicted in blue and the carboxy-terminal helix in gray.  
 
Under normal conditions, Abl is regulated with very low kinase activity, while in chronic 
myelogenous leukemia (CML), it is controlled by a series of intramolecular interactions 
from both SH3 and SH2 domains. Enzymatic studies of Bcr-Abl suggest the native enzyme 
may be distinguished into two principle components, being active and 
inactive/autoinhibited 12. 
 
One of the most promising new drug therapies for CML is Asciminib. This drug binds 
allosterically to Bcr-Abl, targeting the myristoyl pocket (allosteric site to which natural 
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substrate, myristate binds) of the protein. In physiological conditions, the myristoylated N-
terminus of ABL acts as a regulator of kinase activity, however, this is lost upon fusion 
with BCR in CML. The Asciminib drug was designed to restore the autoregulatory function 
of  Bcr-Abl  fusion protein, thus inhibiting oncogenic signaling. Recent studies have shown 
that monotherapy using Asciminib led to tumor regression in mice xenografted with 
KCL22 CML cell line. Despite this, however, all of the tumors eventually recurred 13–15. 
Although this drug has been proven to inhibit the Bcr-Abl protein in multiple studies16 , 
there are also numerous investigations on Asciminib-resistance susceptibility in multiple 
CML cell lines13,17,18.  
 
Imatinib has been previously reported to competitively bind to the ATP active site, thus 
leading to a loss in Bcr-Abl activity and an eventual suppression of CML 19.  Nilotinib, is 
structurally similar to the Imatinib, but with molecular alterations that provide higher 
affinity towards Bcr-Abl. Nilotinib is 10 to 50-fold more potent than Imatinib against ABL 
and shows higher efficacy against multiple CML mutants. The drug, together with Dastinib 
has been previously used against drug resistant CML, with Nilotinib being approved by the 
FDA as a drug of choice for the treatment of patients who become resistant to imatinib or 
in advanced stage of the disease 20–24. Nilotinib has also been used as a multitherapy, 
treating various proteins including ABL, PDGFRA and KIT in gastrointestinal stromal 
tumors, as well as acute and chronic myeloid leukemia 25. Figure 4.2 shows the structures 
of the currently available drugs against Bcr-Abl.  
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Figure 4.2: The 2-D structures of Bcr-Abl inhibitors: (left) Imatinib, (centre) Nilotinib, 
(right) Asciminib. 
 
Combination therapy involving both catalytic and allosteric site inhibitors have shown 
abundant potential in improving the outcome of CML treatment and overcoming 
monotherapeutic resistance 13,15. With the availability of drugs for both the allosteric and 
active site, there is an urgent need to get new insights into the structural basis of potential 
dual inhibition. This would allow for a greater understanding of effective co-administrative 
treatments against CML. A recent study by Wylie et al (2017) demonstrated, with the use 
of NMR and crystallography, the dual targeting of Bcr-Abl with potent inhibitor Asciminib 
at the allosteric, myristoyl pocket of the protein and Nilotinib at the catalytic pocket 17. 
These results indicated Asciminib bound in a similar conformation to that of myristate and 
when bound in combination with Nilotinib, led to tumour regression in mice. It was 
interesting to note that even after the stopping the combination dosage, no evidence of 
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tumor re-growth was observed. To further assess the dosage of Asciminib in CML patients, 
a phase 1 clinical trial was initiated (ClinicalTrials.gov identifier: NCT02081378). To 
further validate the study, a crystal structure of the protein in complex with both Nilotinib 
and Asciminib was reported (PDB code: 5MO4) 17. Preliminary results on patients 
receiving an escalated dose of the compound revealed well-tolerated dose-dependent 
pharmacokinetics.  Other studies by Cowan-Jacob (2016) and Schoepfer et al (2018) 
further exemplified the potency of Asciminib as an allosteric inhibitor against the Bcr-Abl  
protein in CML 26,27. Based on the above-mentioned experimental investigation, we 
present, in this study, the first account of the structural mechanism of inhibition induced 
by co-binding of allosteric (Asciminib) and catalytic (Nilotinib) inhibitors (Figure 4.3).  
 
Figure 4.3: Schematic representation of the conformational equilibrium of Bcr-Abl in open 
and closed states in the presence and absence of inhibitors, [A] Apo Bcr-Abl active flexible, 
Without a ligand bound to the Allosteric site, the carboxy-terminal helix is flexible [B] 
Binding of nilotinib to the catalytic site shifts this equilibrium to the open state (active 
form) [C] Binding of Asciminib to the allosteric site fixes the carboxy-terminal helix (blue) 
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and stabilizes the closed state by reducing steric clashes. [D] Combined binding of 
Nilotinib and Asciminib shifts the equilibrium to the closed state (inactive rigid 
conformation).  
 
Multi-targeted therapies have become extremely popular in cancer treatments over recent 
years. A study by Block et al., (2015) described the feasibility of therapeutics against a 
wide range of cancer targets, thus eliminating the potential of drug resistance as observed 
with monotherapies 28. Molecules that control cell proliferation and death, including 
tyrosine kinase receptors can be targeted with two classes of compounds, being 
trastuzamab and imatinib. The main concern with these compounds is the problem of 
relapse and resistance 29. Based on these results, there is now an agreement that molecules 
that target multiple agents may be more effective. Our study aims to add to the broad-
spectrum approach elucidated on in the above-mentioned article, thus increasing the 
number of combinatorial low-toxicity agents that will simultaneously inhibit a network of 
targets in cancer metabolism.  
By the utilization of a wide range of in silico tools, we define and compare Bcr-Abl’s 
structural and dynamic characteristics when bound as a dual inhibitor system. Furthermore, 
we provide a binding landscape of this synergistic dual inhibition, thus providing an 
attenuation mechanism for Asciminib-resistance. Further studies beyond this investigation 
will be to test the dual inhibitory mechanism on other cancer targets, thus increasing the 
chance of a multitherapeutic combination.  
4.2 Computational Methods 
4.2.2 System Preparation  
The Bcr-Abl tyrosine kinase in complex with PD166326 and Myristic acid (PDB code: 
1OPK)12 was obtained from RSCB Protein Data Bank30. Although the crystal structure 
used in the study originates from the Mus musculus organism, superimposition of the 
crystal structure to mutated human Bcr-Abl (PDB code: 5MO4)17 shows no significant 
structural or sequential differences between the organisms, thus permitting structural 
extrapolation to human CML (Figure S1). The 3-D structure of the inhibitors, Nilotinib and 
 78 
Asciminib, were obtained from PubChem31. The Apo structure was prepared by manually 
deleting the solvent and any bound small molecules from the crystal structure. Docking 
was carried on both catalytic and allosteric active sites using Autodock Vina32 to obtain the 
Nilotinib, Asciminib and Nilotinib-Asciminib complexes. In total, four systems were 
subjected to 190ns molecular dynamic simulations as described in “Molecular Dynamic 
Simulations” section. Protein and ligand alterations as well as visualizations were 
conducted in Chimera software 33.  
4.2.2 Molecular Dynamic (MD) Simulations 
Molecular dynamic (MD) simulations are an important tool to determine the physical 
movements of atoms and molecules, thus providing insights on the dynamical evolution of 
biological systems34. The MD simulations were carried out on the systems using the GPU 
version of AMBER 14, with an integrated SANDER module and the FF14SB variant of 
the AMBER force field35. This was followed by a standard simulation protocol previously 
adopted in our preceding studies 36–38. 
4.2.3Post-Dynamic Analysis 
The coordinates of the complexes were each saved every 1 ps, followed by analysis using 
the CPPTRAJ39 module employed in AMBER 14 suit. All plots were completed using the 
Origin data analysis tool and Chimera33.  
4.2.4 Binding Free Energy Calculations 
 
Calculation of the binding fee energy of small ligand to protein is one of the most important 
end point methods currently used in computational biophysics 40. To determine the free 
binding energy of each system, the Molecular Mechanics/GB Surface Area method 
(MM/GBSA) was employed41. The explicit solvent employed in the MD simulation was 
discarded and replaced with a dielectric continuum 42 . The changes (∆) in each term 
between complex state and unbound state were calculated and contributed to the total 
relative binding free energy 42. Molecular mechanics force fields were then employed to 
calculate energy contributions from the atomic coordinates of the enzyme, ligands and the 
complex in a gas phase 42. 
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Binding free energy was averaged over 19,000 snapshots extracted from the 190ns 
trajectory. The free binding energy (ΔG) calculated by this method for each molecular 
species employs typical molecular mechanic equations, which have been elaborated on in 
a number of our previous publications 38,43 and will not be reiterated herein.  
4.3 Results and Discussion 
4.3.1 Synergistic Duality: Allosteric versus Catalytic Inhibition  
The basic concept of catalytic inhibition can be explained as a competitive mechanism. In 
CML conditions, the natural substrate, in this instance, ATP, would bind to the active site 
of Bcr-Abl and allow for continued deregulated tyrosine kinase activity. When a 
competitive inhibitor, such as Nilotinib, is administered, it would compete with ATP to 
bind to the active site. In most cases, drugs are designed to bind more strongly than that of 
the natural substrate, this allows sustained inhibition of the protein. However, if it were 
that simple for a drug to inhibit a protein, there would be no need for the design of new, 
more effective treatments. Drug resistance and adverse molecular interactions mainly due 
to target mutations have opened the drug discovery domain to identifying alternative means 
of inhibiting a drug target. Allosteric inhibition entails the binding of a drug to a 
hydrophobic pocket, other than the active site, thus affecting the conformation of the 
catalytic region and inhibiting binding of the natural substrate. In the case of CML, 
however, the Bcr-Abl has shown resistance to allosteric binding of Asciminib alone 44, 
therefore requiring researchers to go back to the drawing board. To further explain the 
synergistic dual targeting that Wylie et al., (2017) proposed experimentally, Asciminib 
binds to the allosteric, myristoyl pocket with a higher affinity than that of myristoyl 17. 
Intramolecular interactions than occur between the molecular groups of Asciminib and the 
allosteric site amino acids, which lead to structural modifications of the enzyme, eventually 
leading to modification of the catalytic site, allowing for increased interactions upon 
binding of Nilotinib. These structural dynamics that allow for this synergistic inhibition is 
elucidated on below. The binding free energy changes are also presented to corroborate the 




4.3.2 Drug duality leads to an unwavering structural ensemble 
The Bcr-Abl protein contains a characteristic “activation loop” that remains in a closed 
position whilst inactivated and opens out when the protein is to be activated. Studies have 
shown that the site in which Nilotinib binds to allows for this activation loop to remain 
closed and thus inactive 45. To assess this theory, snapshots were taken at 80ns, to identify 
whether each complex remained closed subsequent to the binding of Nilotinib. It was 
evident from these snapshots that the characteristic loop remained in a closed position 
among all three complexes.  
 
The stability of the MD simulation was determined by measuring the variations in the root 
mean square deviation (RMSD) of the C-α atoms across the 190ns trajectory. The RMSD 
results for all the systems are illustrated in Figure 4. All systems reached convergence after 
approximately 125 ns (RMSD deviation < 2 °A). The Asciminib (2.89Å) and Nilotinib 
(2.93Å) systems showed much higher RMSD fluctuations throughout the simulation 




Figure 4.4: Root-mean-square deviation (RMSD) of the backbone atoms relative to the 
starting minimized structure over 190ns simulation for Apo, Asciminib, Nilotinib and 
Asciminib-Nilotinib systems. The “activation loop” of each system showed a closed 
structure, indicating a inactive protein.  
 
The root mean square fluctuation (RMSF) of each residue in all four systems was analyzed 
to determine Bcr-Abl’s structural changes upon ligand binding. Figure 4.5 clearly 
demonstrates greater residue fluctuations in the Asciminib system (14.54Å). This may be 
due to Bcr-Abl’s flexibility to a closed state and previously illustratedL001 in figure 3. It 
is interesting to note that of the four systems, the Asciminib-Nilotinib system is the most 
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stable (9.98Å). This may be due to Nilotinib binding to the catalytic site of Bcr-Abl. These 
results could be potentially extrapolated to reveal that dual binding decreases the overall 
flexibility of Bcr-Abl (inactive form). 
 
Figure 4.5: The RMSF of Bcr-Abl in each of the four systems relative to the starting 
minimized structure over 190 ns simulation. 
 
The radius of gyration (Rg) was performed to give insights into the distribution of atoms 
from the center of mass of the complexes during MD simulations 46,47.  The Apo, 
Asciminib, Nilotinib and Asciminib-Nilotinib systems were measured, analyzed, and 
plotted as seen in figure S1. The Rg between the systems showed very similar structural 
 83 
compactness, however, atomic distribution was seen in the Asciminib-Nilotinib system 
from 170-180ns.  
 
Usually protein interactions are often accomplished by significant changes in the 
conformation, from folding to the unfolding of a protein. Bcr-Abl conformation studies 
had shown that the protein misfolding characterized its activity, indicating that the folded 
state characterized its activity 48,49. To further support this statement, Solvent accessible 
surface area (SASA) was used to predict and determine the magnitude of compactness of 
each system’s hydrophobic core (Figure S2). This was done by calculating the surface area 
of the protein visible to solvent across the duration of the molecular dynamics simulation 
which is essential in biomolecular stability 50.  
 
Extrapolating from figure S1, the Asciminib-Nilotinib system showed an average surface 
area of 20578.21Å, indicating greater compactness compared to the rest of the systems. 
This, together with the results from RSMD, RMSF and radius of gyration prove that co-
administration of Asciminib and Nilotinib results in a stable and more compact Bcr-Abl 
protein.  
 
The results obtained from the above analysis prompted us to explore the thermodynamic 
binding landscape of Asciminib and Nilotinib to Bcr-Abl.  
 
4.3.3 Co-binding of Asciminib and Nilotinib acts as a “thermodynamic safety-net” 
 
To gain insight into the energetics of Bcr-Abl binding to Asciminib and Nilotinib, the total 
binding free energy of the three systems being, Asciminib and Nilotinib alone and then 
upon co-binding of the two drugs. The MM/GBSA approach was utilized to better 
understand the various energy contributions within the binding pocket.  
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As seen in Table 4.1, the difference in binding energy of Nilotinib when bound alone (-
31.68 kcal/mol) to when co-bound (-38.19 kcal/mol) was 6.51 kcal/mol. This indicates 
more favorable binding when bound together with Asciminib. Although showing a smaller 
difference, the Asciminib also showed greater intramolecular energy when co-bound. The 
computed binding energies correlate well with the experimental IC50 reported values 
13,15. 
The thermodynamic energy contribution of Nilotinib to the total binding free energy of the 
complex surmounts to the stability of Asciminib in the allosteric binding pocket and thus 
the stability of the complex during the simulation.  
Table 4.1: Summary of free binding Energy contributions of Asciminib, Nilotinib and 
Asciminib-Nilotinib systems.  
Energy Components (kcal/mol) 
Individual Binding of Ligands 
 
 
Δ EvdW ΔEelec ΔGgas ΔGsolv ΔGbind 
Asciminib -47.74±0.06 -20.29±0.14 -68.04±0.17 28.99±0.12 -39.04±0.08 
Nilotinib 
-45.19 ± 0.06 -142.23 ± 0.58 -187.43 ± 0.57 -159.75 ± 0.55 -31.68 ± 0.062 
 
Co-binding of Ligands 
 
 
Δ EvdW ΔEelec ΔGgas ΔGsolv ΔGbind 
Asciminib -48.33±0.38 -165.10±1.13 -213.44±1.00 -173.60±0.96 -39.83±0.23 




As evident from Table 1, that the electrostatic, Gibbs free energy, and solvation interactions 
were found to be the most favorable energy contributors to both Asciminib, Nilotinib 
binding to the protein.  
 
Figure 4.6 illustrates the collective drug-binding landscape at an atomistic level. Catalytic 
site residues Asn259 and Thr252 formed stable hydrogen bonds with the hydroxyl and 
amino group of Nilotinib, while the amino group of Asciminib donated a hydrogen bond 
to residue Glu399. It is also interesting to note that highly electrostatic fluorine molecules 
were found at the based of the hydrophobic pocket in both the catalytic and active sites.  
 
Figure 4.6: Surface representation of dual catalytic and allosteric inhibition of Bcr-Abl by 
Nilotinib and Asciminib. Nilotinib binds at the catalytic site while Asciminib binds at the 
allosteric pocket. Ligand interaction plot illustrates interactions between binding site 
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residues and the above drugs (grey haze demonstrates ionic interactions, pink arrows show 
hydrogen bonds and coloured lines indicate hydrophobic energy).  
 
Based on the evidence from the above analysis, it may be deduced that the co-bound system 
demonstrated a more stable and compact system compared to the Apo and monotherapeutic 
systems. This corresponds to the thermodynamic energy calculations that displayed that 
the co-bound system had greater binding energies. Correlation of these results confers with 
the experimentally demonstrated synergistic effects generated upon co-binding of 
Asciminib and Nilotinib 15. 
 
4.4 Conclusion  
Computational analytical approaches were used to understand the dual inhibitory 
mechanism of Nilotinib and Asciminib against Bcr-Abl.  To this end, comparative MD 
simulations and analyses were performed toward determining the binding landscape and 
structural features that are characteristic of this synergistic dual inhibition. Our findings 
correlated with earlier experimental studies reporting co-administration of these two drugs. 
Results demonstrated that the co-bound Bcr-Abl system induced a more stable, compact 
protein structure, when compared to systems in which Asciminib and Nilotinib were 
individually bound. Thermodynamic calculations indicated that Nilotinib exerts some level 
of stability and stronger Asciminib-Bcr-Abl interactions. As a result, the calculated binding 
free energy of Asciminib in the presence of Nilotinib was higher compared to when bound 
alone as elucidated in the thermodynamics. These revelations give insights into the possible 
structural dynamics at play, thus contributing to the experimental co-administration 
studies. We believe that this study will aid in the understanding synergistic dual inhibition 






The authors acknowledge the Center for High Performance Computing 























(1)  Deininger, M. W. Diagnosing and Managing Advanced Chronic Myeloid Leukemia. 
Am. Soc. Clin. Oncol. Educ. B. 2015, 35, e381–e388.  
(2)  Granatowicz, A.; Piatek, C. I.; Moschiano, E.; El-Hemaidi, I.; Armitage, J. D.; 
Akhtari, M. An Overview and Update of Chronic Myeloid Leukemia for Primary 
Care Physicians. Korean J. Fam. Med. 2015, 36 (5), 197–202.  
(3)  Baccarani, M.; Pileri, S.; Steegmann, J.-L.; Muller, M.; Soverini, S.; Dreyling, M. 
Chronic Myeloid Leukemia: ESMO Clinical Practice Guidelines for Diagnosis, 
Treatment and Follow-Up. Ann. Oncol. 2012, 23, vii72-vii77.  
(4)  Matutes, E.; Pickl, W. F.; van’t Veer, M.; Morilla, R.; Swansbury, J.; Strobl, H.; 
Attarbaschi, A.; Hopfinger, G.; Ashley, S.; Bene, M. C.; et al. Mixed-Phenotype 
Acute Leukemia: Clinical and Laboratory Features and Outcome in 100 Patients 
Defined According to the WHO 2008 Classification. Blood 2011, 117 (11), 3163–
3171.  
(5)  Clark, S. S.; McLaughlin, J.; Timmons, M.; Pendergast, A. M.; Ben-Neriah, Y.; 
Dow, L. W.; Crist, W.; Rovera, G.; Smith, S. D.; Witte, O. N. Expression of a 
Distinctive BCR-ABL Oncogene in Ph1-Positive Acute Lymphocytic Leukemia 
(ALL). Science 1988, 239 (484), 775–777. 
(6)  Konopka, J. B.; Watanabe, S. M.; Witte, O. N. An Alteration of the Human C-Abl 
Protein in K562 Leukemia Cells Unmasks Associated Tyrosine Kinase Activity. 
Cell 1984, 37 (3), 1035–1042. 
(7)  Laneuville, P. Abl Tyrosine Protein Kinase. Semin. Immunol. 1995, 7 (4), 255–266.  
(8)  Liu, J.; Campbell, M.; Guo, J. Q.; Lu, D.; Xian, Y. M.; Andersson, B. S.; Arlinghaus, 
R. B. BCR-ABL Tyrosine Kinase Is Autophosphorylated or Transphosphorylates 
P160 BCR on Tyrosine Predominantly within the First BCR Exon. Oncogene 1993, 
8 (1), 101–109. 
(9)  Pendergast, A. M.; Quilliam, L. A.; Cripe, L. D.; Bassing, C. H.; Dai, Z.; Li, N.; 
Batzer, A.; Rabun, K. M.; Der, C. J.; Schlessinger, J. BCR-ABL-Induced 
 89 
Oncogenesis Is Mediated by Direct Interaction with the SH2 Domain of the GRB-2 
Adaptor Protein. Cell 1993, 75 (1), 175–185. 
(10)  Ben-Neriah, Y.; Daley, G. Q.; Mes-Masson, A. M.; Witte, O. N.; Baltimore, D. The 
Chronic Myelogenous Leukemia-Specific P210 Protein Is the Product of the 
Bcr/Abl Hybrid Gene. Science 1986, 233 (4760), 212–214. 
(11)  Yang, J.; Campobasso, N.; Biju, M. P.; Fisher, K.; Pan, X.-Q.; Cottom, J.; Galbraith, 
S.; Ho, T.; Zhang, H.; Hong, X.; et al. Discovery and Characterization of a Cell-
Permeable, Small-Molecule c-Abl Kinase Activator That Binds to the Myristoyl 
Binding Site. Chem. Biol. 2011, 18 (2), 177–186.  
(12)  Nagar, B.; Hantschel, O.; Young, M. A.; Scheffzek, K.; Veach, D.; Bornmann, W.; 
Clarkson, B.; Superti-Furga, G.; Kuriyan, J. Structural Basis for the Autoinhibition 
of C-Abl Tyrosine Kinase. Cell 2003, 112 (6), 859–871. 
(13)  Wylie, A.; Schoepfer, J.; Berellini, G.; Cai, H.; Caravatti, G.; Cotesta, S.; Dodd, S.; 
Donovan, D.; Erb, B.; Furet, P.; Gangal, G.; Grotzfeld, R.; Hassan, Q.; Hood, T.; 
Iyer, I.; Jacob, S.; Ja, W. ABL001, a Potent Allosteric Inhibitor of BCR-ABL, 
Prevents Emergence of Resistant Disease When Administered in Combination with 
Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia. Blood 2014, 
124, 398–398. 
(14)  Eadie, L. N.; Saunders, V. A.; Leclercq, T. M.; Branford, S.; White, D. L.; Hughes, 
T. P. The Allosteric Inhibitor ABL001 Is Susceptible to Resistance in Vitro 
Mediated By Overexpression of the Drug Efflux Transporters ABCB1 and ABCG2. 
Blood 2015, 126 (23), 4841–4841. 
(15)  Wylie, A. A.; Schoepfer, J.; Jahnke, W.; Cowan-Jacob, S. W.; Loo, A.; Furet, P.; 
Marzinzik, A. L.; Pelle, X.; Donovan, J.; Zhu, W.; et al. The Allosteric Inhibitor 
ABL001 Enables Dual Targeting of BCR? ABL1. Nature 2017, 543 (7647), 733–
737.  
(16)  Ottmann, O. G.; Alimena, G.; DeAngelo, D. J.; Goh, Y.-T.; Heinrich, M. C.; 
Hochhaus, A.; Hughes, T. P.; Mahon, F.-X.; Mauro, M. J.; Minami, H.; et al. 
 90 
ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising 
Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior 
TKI Therapy. Blood 2015, 126 (23), 138–138. 
(17)  Wylie, A. A.; Schoepfer, J.; Jahnke, W.; Cowan-Jacob, S. W.; Loo, A.; Furet, P.; 
Marzinzik, A. L.; Pelle, X.; Donovan, J.; Zhu, W.; et al. The Allosteric Inhibitor 
ABL001 Enables Dual Targeting of BCR–ABL1. Nature 2017, 543 (7647), 733–
737.  
(18)  Hughes, T. P.; Goh, Y.-T.; Ottmann, O. G.; Minami, H.; Rea, D.; Lang, F.; Mauro, 
M. J.; DeAngelo, D. J.; Talpaz, M.; Hochhaus, A.; et al. Expanded Phase 1 Study of 
ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and 
Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI 
Therapy. Blood 2016, 128 (22), 625–625. 
(19)  Druker, B. J.; Sawyers, C. L.; Kantarjian, H.; Resta, D. J.; Reese, S. F.; Ford, J. M.; 
Capdeville, R.; Talpaz, M. Activity of a Specific Inhibitor of the BCR-ABL 
Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute 
Lymphoblastic Leukemia with the Philadelphia Chromosome. N. Engl. J. Med. 
2001, 344 (14), 1038–1042.  
(20)  Hassan, A. Q.; Sharma, S. V.; Warmuth, M. Allosteric Inhibition of BCR-ABL. Cell 
Cycle 2010, 9 (18), 3734–3738.  
(21)  Giles, F. J.; Le Coutre, P. D.; Pinilla-Ibarz, J.; Larson, R. A.; Gattermann, N.; 
Ottmann, O. G.; Hochhaus, A.; Radich, J. P.; Saglio, G.; Hughes, T. P.; et al. 
Nilotinib in Imatinib-Resistant or Imatinib-Intolerant Patients with Chronic Myeloid 
Leukemia in Chronic Phase: 48-Month Follow-up Results of a Phase II Study. 
Leukemia 2013, 27 (1), 107–112.  
(22)  Rogers, G.; Hoyle, M.; Thompson Coon, J.; Moxham, T.; Liu, Z.; Pitt, M.; Stein, K. 
Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Myeloid 
Leukaemia: A Systematic Review and Economic Evaluation. Health Technol. 
Assess. 2012, 16 (22), 1–265. 
 91 
(23)  Jarwoski, A.; Sweeney, R. P. Nilotinib : A New Tyrosine Kinase Inhibitor for the 
Treatment of Chronic Myelogeneous Leukemia. Pharmacotherapy 2008, 28 (11), 
1374–1382.  
(24)  Blay, J. Y.; Von Mehren, M. Nilotinib: A Novel, Selective Tyrosine Kinase 
Inhibitor. Semin. Oncol. 2011, 38 (1), 1–13.  
(25)  Bleeker, F. E.; Bardelli, A. Genomic Landscapes of Cancers: Prospects for Targeted 
Therapies. Pharmacogenomics 2007, 8 (12), 1629–1633.  
(26)  Cowan-Jacob, S. W. The Role of Structure and Biophysics in the Discovery of 
Allosteric Kinase Inhibitors: ABL001, a Potent and Specific Inhibitor of BCR-ABL. 
Acta. Crystallogr. 2016, 72 (a1), s4–s5.  
(27)  Schoepfer, J.; Jahnke, W.; Berellini, G.; Buonamici, S.; Cotesta, S.; Cowan-Jacob, 
S. W.; Dodd, S.; Drueckes, P.; Fabbro, D.; Gabriel, T.; et al. Discovery of Asciminib 
(ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of Bcr-Abl1. J. 
Med. Chem. 2018, 61 (18), 8120–8135.  
(28)  Block, K. I.; Gyllenhaal, C.; Lowe, L.; Amedei, A.; Ruhul Amin, A. R. M.; Amin, 
A.; Aquilano, K.; Arbiser, J.; Arreola, A.; Arzumanyan, A.; et al. Designing a Broad-
Spectrum Integrative Approach for Cancer Prevention and Treatment. Semin. 
Cancer Biol. 2015, 35 (3), S276–S304. 
(29)  Giordano, S.; Petrelli, A. From Single- to Multi-Target Drugs in Cancer Therapy: 
When Aspecificity Becomes an Advantage. Curr. Med. Chem. 2008, 15 (5), 422–
432.  
(30)  Berman, H. M.; Battistuz, T.; Bhat, T. N.; Bluhm, W. F.; Philip, E.; Burkhardt, K.; 
Feng, Z.; Gilliland, G. L.; Iype, L.; Jain, S.; et al. The Protein Data Bank. Biol. 
Crystallogr. 2002, 58, 899–907. 
(31)  Kim, S.; Thiessen, P. A.; Bolton, E. E.; Chen, J.; Fu, G.; Gindulyte, A.; Han, L.; He, 
J.; He, S.; Shoemaker, B. A.; et al. PubChem Substance and Compound Databases. 
Nucl. A. Res. 2016, 44 (1), 1202–1213. 
(32)  Trott, O.; Olson, A. J. AutoDock Vina: Improving the Speed and Accuracy of 
 92 
Docking with a New Scoring Function, Efficient Optimization, and Multithreading. 
J. Comput. Chem. 2010, 31 (2), 455–461. 
(33)  Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; 
Meng, E. C.; Ferrin, T. E. UCSF Chimera--a Visualization System for Exploratory 
Research and Analysis. J. Comput. Chem. 2004, 25 (13), 1605–1612.  
(34)  Adcock, S. A.; McCammon, J. A. Molecular Dynamics: Survey of Methods for 
Simulating the Activity of Proteins. Chem. Rev. 2006, 106 (5), 1589–1615.  
(35)  Case, D. A.; Cheatham, T. E.; Darden, T.; Gohlke, H.; Luo, R.; Merz, K. M.; 
Onufriev, A.; Simmerling, C.; Wang, B.; Woods, R. J. The Amber Biomolecular 
Simulation Programs. J. Comput. Chem. 2005, 1668–1688. 
(36)  Ramharack, P.; Soliman, M. E. S. Zika Virus NS5 Protein Potential Inhibitors: An 
Enhanced in Silico Approach in Drug Discovery. J. Biomol. Struct. Dyn. 2018, 36 
(5), 1118–1133.  
(37)  El Rashedy, A. A.; Olotu, F. A.; Soliman, M. E. S. Dual Drug Targeting of Mutant 
Bcr-Abl Induces Inactive Conformation: New Strategy for the Treatment of Chronic 
Myeloid Leukemia and Overcoming Monotherapy Resistance. Chem. Biodivers. 
2018.  
(38)  Ramharack, P.; Oguntade, S.; Soliman, M. E. S. Delving into Zika Virus Structural 
Dynamics – a Closer Look at NS3 Helicase Loop Flexibility and Its Role in Drug 
Discovery. RSC Adv. 2017, 7 (36), 22133–22144.  
(39)  Roe, D. R.; Cheatham, T. E. PTRAJ and CPPTRAJ: Software for Processing and 
Analysis of Molecular Dynamics Trajectory Data. J. Chem. Theory Comput. 2013, 
9, 3084–3095. 
(40)  Ylilauri, M.; Pentikäinen, O. T. MMGBSA as a Tool to Understand the Binding 
Affinities of Filamin-Peptide Interactions. J. Chem. Inf. Model. 2013, 53 (10), 2626– 
(41)  Hou, T.; Wang, J.; Li, Y.; Wang, W. Assessing the Performance of the MM/PBSA 
and MM/GBSA Methods. 1. The Accuracy of Binding Free Energy Calculations 
Based on Molecular Dynamics Simulations. J. Chem. Inf. Model. 2011, 51 (1), 69–
 93 
82.  
(42)  Hayes, J. M.; Archontis, G. MM-GB (PB) SA Calculations of Protein-Ligand 
Binding Free Energies. InTech 2011, 171–190.  
(43)  Agoni, C.; Ramharack, P.; Soliman, M. E. S. Co-Inhibition as a Strategic 
Therapeutic Approach to Overcome Rifampin Resistance in Tuberculosis Therapy: 
Atomistic Insights. Future Med. Chem. 2018, 10 (14), 1665–1675.  
(44)  Eadie, L. N.; Saunders, V. A.; Branford, S.; White, D. L.; Hughes, T. P. The New 
Allosteric Inhibitor Asciminib Is Susceptible to Resistance Mediated by ABCB1 
and ABCG2 Overexpression. Oncotarget 2018, 9 (17), 13423–13437.  
(45)  Reddy, E. P.; Aggarwal, A. K. The Ins and Outs of Bcr-Abl Inhibition. Genes and 
Cancer 2012, 3 (5–6), 447–454.  
(46)  Pan, L.; Patterson, J. C.; Deshpande, A.; Cole, G.; Frautschy, S. Molecular 
Dynamics Study of Zn(Aβ) and Zn(Aβ)2. PLOS ONE 2013, 8 (9), e70681.  
(47)  Wijffels, G.; Dalrymple, B.; Kongsuwan, K.; Dixon, N. Conservation of Eubacterial 
Replicases. IUBMB. Life 2005, 57 (6), 413–419.  
(48)  Panjarian, S.; Iacob, R. E.; Chen, S.; Engen, J. R.; Smithgall, T. E. Structure and 
Dynamic Regulation of Abl Kinases. J. Biol. Chem. 2013, 288 (8), 5443–5450.  
(49)  Maru, Y. Molecular Biology of Chronic Myeloid Leukemia. Cancer Sci. 2012, 103 
(9), 1601–1610.  
(50)  Marsh, J. A.; Teichmann, S. A. Relative Solvent Accessible Surface Area Predicts 









Dual drug targeting of mutant Bcr-Abl induces inactive conformation: New strategy 
for the treatment of chronic myeloid leukemia and overcoming monotherapy 
resistance  
 
Ahmed A El Rashedya, Fisayo A. Olotua, Mahmoud E. S. Solimana,b* 
 
aMolecular Modeling and Drug Design Research Group, School of Health Sciences, 
University of KwaZulu-Natal, Westville Campus, Durban 4001, South Africa 
bCollege of Pharmacy and Pharmaceutical Sciences, Florida Agricultural and Mechanical 
University, FAMU, Tallahassee, Florida 32307, USA. 
 
*Corresponding Author: Mahmoud E.S. Soliman 
Email: soliman@ukzn.ac.za  









Bcr-Abl is an oncogenic fusion protein which expression enhances tumorigenesis, and has 
been highly associated with chronic myeloid leukemia (CML). Acquired drug resistance 
in mutant Bcr-Abl has enhanced pathogenesis with the use of single therapy agents such 
as Nilotinib. Moreover, allosteric targeting has been identified to consequentially inhibit 
Bcr-Abl activity, which led to the recent development of ABL-001 (asciminib) that 
selectively binds the myristoyl pocket. Experimental studies have revealed that the 
combination of Nilotinib and ABL-001 induced a "bent" conformation in the C-terminal 
helix of Bcr-Abl; a benchmark of inhibition, thereby exhibiting a greater potency in the 
treatment of CML, surmounting the setbacks of drug resistance, disease regression and 
relapse. Therefore, we report the first account of the dynamics and conformational analysis 
of oncogenic T334I Bcr-Abl by dual targeting. Our findings revealed that unlike in the Bcr-
Abl-Nilotinib complex, dual targeting by both inhibitors induced the bent conformation in 
the C-terminal helix that varied with time. This was coupled with significant alteration in 
Bcr-Abl stability, flexibility and compactness and an overall structural re-orientation 
inwards towards the hydrophobic core, which reduced the solvent-exposed residues 
indicative of protein folding. This study = will facilitate allosteric targeting and the design 
of more potent allosteric inhibitors for resistive target proteins in cancer. 
 










The success of targeted therapy with kinase inhibitors has been best shown in Bcr-Abl, 
wherein a drug such as imatinib selectively diminishes kinase activity with significant 
pharmacological effect in the treatment of chronic myelogenous leukemia (CML) 1. 
However, the potency of kinase inhibitors in cancer therapeutics has been invariably 
impeded by the emergence of acquired resistance, thereby presenting one of the major 
challenges to the effective deployment of these agents in the clinic 1. Prior to oncogenesis, 
activation of Abelson tyrosine kinase (ABL) occurs by the combination of the BCR 
(breakpoint cluster region) gene with the gene that codes for the intracellular non-receptor 
tyrosine kinase, which translates into the formation of an enormous protein of 
approximately 1150 residues. This possesses two distinct halves; the N-terminal half 
constitutes an N-terminal cap, SH3 and an SH2 domain sequentially while the C-terminal 
half is made up response elements for varying functionality, which includes domain for 
DNA and actin binding 2. This is in close proximity to the phosphorylation site in the C-
terminal half, and also includes proline-rich segments for nuclear localization and export 
signaling 3. The N-terminal cap contains an approximate of 80 residues that play critical 
role in autoinhibition. This domain is followed by the SH3 domain, SH2 and ultimately a 
tyrosine kinase domain (Nagar et al. 2003). The interaction between the SH3 and the SH2 
domains facilitates autoinhibition, which involves the binding of the SH3 domain to the 
linker sequence (polyproline) between the SH2 and kinase domains. This is followed by 
the interaction between the SH2 domain and the kinase domain’s C-terminal lobe to form 
a clamp structure (Hantschel et al. 2003; Nagar et al. 2006). The binding of the SH3 
domains to peptides to form polyproline type II helices while on the other hand, SH2 
domains interact with and bind to peptides that contain phosphotyrosine. In its normal state, 
the c-Abl is regulated with very low kinase activity, while in diseased states such as in 
chronic myeloid leukemia (CML), it is upregulated by a complex intramolecular interplay 
between the SH2, SH3, and the kinase domain 4, 5. In this case, oncogenic activation is 
driven by the fusion of Bcr to c-Abl at its NH2 terminus (Hantschel et al. 2003; Panjarian 
et al. 2013). The linker region between SH2 and catalytic domains form a polyproline type 
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II helix, which binds the SH3 domain, bringing it into close proximity with the catalytic 
domain 4 (Figure 5.1). 
 
Figure 5.1: Structural highlight of Bcr-Abl domains showing the SH2, SH3, kinase 
domains and the C-terminal helix. 
Regulation of c-Abl occurs via an autoinhibitory mechanism, which has been elucidated to 
occur through the binding of myristoyl to the myristoyl pocket, an allosteric site situated 
on c-Abl. This results in its conformational reorientation to an inactive auto-inhibited 
kinase state evidenced by the bending of the C-terminal helix 6. However, Bcr-Abl is not 
myristoylated due to the absence of the first Abl exon and the disruption of its regulatory 
mechanism by pertinent auto-phosphorylation results into uncontrolled oncogenic activity 
as seen in chronic myeloid leukemia 6. Inactivation of c-Abl has been the basis of CML 
therapy and this has resulted into the design and use of imatinib, a target specific ATP-
competitive inhibitor which functions by blocking the binding of ATP to the catalytic site, 
leading to the inactivity of Bcr-Abl and eventual amelioration of CML and improves 
overall survival of patients 7. However, point mutations, which occur at this domain, has 
accounted for acquired resistance and reduced sensitivity to imatinib therapy. 
Advancement in therapeutic intervention led to the development of more potent kinase 
inhibitors such as nilotinib and dasatinib to treat CML associated with Imatinib resistance 
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8, 9. Nilotinib (Figure 5.2A) shares more similarity with imatinib in its mode of binding and 
target specificity coupled with its physicochemical properties 10, 11. Although not modified 
by myristoylation, the presence of the pocket for myristate binding on Bcr-Abl presented 
additional target site for therapy, which led to the design of site-specific molecules to 
mimic the binding of myristate and facilitate auto-inhibitory regulation 12. These classes of 
inhibitors are ATP non-competitive but rather bind to the myristoyl pocket of the ABL 
kinase domain 13, thereby decreasing Bcr-Abl aberrant kinase activity. Such inhibitors 
include GNF-2, GNF-5 and most recently, ABL-001 (asciminib), which possesses more 
potency and selectivity among this class of allosteric inhibitors. ABL-001 (Figure 5.2B), 
among others was able to bind specifically at the myristoyl pocket thereby inducing a 
‘bend’ in the C-terminal helix, which structurally characterizes auto-inhibitory modulation 
2, 14.  
 
Figure 5.2: 2D structure of c-Abl inhibitors: [A] Nilotinib [B] ABL-001 
Combination therapy involving both the catalytic and allosteric (myristoyl pocket) 
inhibitors have been identified has a rationale for improving outcomes of CML treatment 
and surmounts setbacks associated with lone administration of either inhibitors such as 
resistance and intolerance 6, 14. In other words, allosteric inhibition complements the 
therapeutic activity of a kinase inhibitor to effect the inactivation of Bcr-Abl oncogenic 
fusion protein as structurally evidenced by the bending of its C-terminal helix. Activated 
Bcr-Abl fusion oncoprotein has been described to exhibit flexibility in the linker chains 
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characteristic of an increased kinase activity while binding of inhibitors to its active and 
allosteric induces rigidity, which is characteristic of inhibited Bcr-Abl (Gray and Fabbro, 
2014; Hantschel, 2012) similar to a c-ABL autoinhibited state for reduced kinase activity 
(Nagar et al. 2006; Panjarian et al. 2013). This is schematically represented below (Figure 
5.3). 
 
Figure 5.3: Schematic representation of the structural effect of single-agent and dual 
inhibition on Bcr-Abl protein complex relative to its activation and inactivation 
conformation. [A] Active flexible and straight C-terminal helix [B] Active flexible and 
straight C-terminal helix [C] Inactive Rigid and bent C-terminal helix conformation. 
There is therefore need to have an insight into the structural basis of dual inhibition in 
abrogating oncogenic Bcr-Abl kinase activity relative to induction of inactive C-terminal 
conformation. Therefore, in this study we present the first account of the dynamics and 
conformational basis of kinase inactivity effected by dual inhibitory mechanisms of 




Figure 5.4: Target site interactions between inhibitors and site residues showing bond 
types involved in stabilization at the respective sites. [A] Nilotinib and catalytic site 
residues [B] ABL-001 and myristoyl-pocket residues 
This is to provide further insight into structural basis of inactivation induced by co-
administration of allosteric and catalytic inhibitors. These findings would further validate 
the rationale of combination therapy in the treatment of CML and also aids the structure-
based design of other potent allosteric inhibitors to enhance the efficacy of kinase 
inhibitors. 
5.2 Result and Discussion  
5.2.1 Protein stability 
Stability of the protein systems was comparatively determined by measuring the root mean 
square deviation (RMSD) of the C-α atoms across the 200ns of the MD simulations. 
Moreover, deviation in protein structure as calculated by the RMSD could correspond to 
the stability of the protein wherein a high value implies a low stability and a low value 
could indicate an increase in protein stability. As seen in Figure 5.5, deviations in both 
systems varied with time wherein a highly unstable structure characterized mutant Bcr-Abl 
inhibited by Nilotinib alone.  
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Figure 5.5: Comparative C-α RMSD plot of single-agent (Nilotinib) and dual 
(Nilotinib+ABL-001) targeted Bcr-Abl complex 
This could suggest one of the basis of mutation-induced acquired resistance to 
monotherapy with the kinase inhibitor; Nilotinib. However, dual targeting by Nilotinib and 
ABL-001 induced a reduction in C-α atoms deviation which could correlate with increase 
in stability. This could provide insight into the structural attributes of mutant Bcr-Abl 
targeted with ABL-001 and Nilotinib in the treatment of CML as revealed experimentally 
14. Average RMSD values include 3.03Å for BN while the allosteric inhibitor lowered the 
deviation to 2.33Å in the BAN complex. 
 
5.2.2 Flexibility and activity interplay 
Conformational studies have associated a compact and rigid structure with an inactive 
oncogenic Bcr-Abl fusion protein while flexibility characterizes its activity and resistance 
2, 15. Therefore, in order to structurally determine the effect of dual inhibition on the 
flexibility protein system, we measured the C-α root mean square fluctuation (RMSF), 
which is a metrics for estimating flexibility. The result revealed that both inhibitors 
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significantly lowered the overall residual fluctuation indicative of rigidity, which 
characterizes the inactive form of the protein (Figure 5.6).  
 
Figure 5.6: C- α RMSF plot showing the effect of single-agent and dual targeting on 
residual fluctuation and overall flexibility relative to inactivation. Inset are the SH3 (red), 
SH2 (gold) and the C-terminal helix (blue). 
In other words, combination of Nilotinib and the allosteric inhibitor; ABL-001 reduces 
flexibility. However, with the catalytic inhibitor, Nilotinib alone, mutant Bcr-Abl 
maintained high flexibility, which characterizes the active form. This could indicate mutant 
Bcr-Abl Nilotinib-resistivity and serve as a basis for structural characterization. Reduction 
in flexibility was revealed as shown in the figure above across the respective domains that 
constitute Bcr-Abl fusion proteins. The complex with both inhibitors (BAN) has an average 
RMSF value of 7.68Å that was significantly lower than in BN: 12.08Å. 
5.2.3 Exposed surface area and protein folding 
The solvent accessible surface area (SASA) analysis is useful in understanding the folding-
unfolding process of a protein in conformational studies as it measures the surface area of 
the protein exposed to solvent across the duration of the molecular dynamics simulation. 
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Moreover, the process of folding decreases the protein surface exposed to the solvent while 
an increase in the exposed surface depicts an unfolding process 16. Conformational Bcr-
Abl studies had also revealed that protein misfolding characterizes its activity while 
inactive in its folded state 17, 18. Our result agrees accordingly as shown in the SASA plot, 
which reveals that allosteric combined with catalytic targeting reduces the number of 
solvent exposed surfaces (Figure 5.7).  
 
Figure 5.7: Comparative SASA plot showing single and dual inhibition-induced exposure 
of surfaces 
This is indicative of protein unfolding which characterizes inactive Bcr-Abl state. 
However, there was an increase in the surfaces exposed to solvent in BN. In other words, 
dual targeting caused an inward re-orientation of residual side chains that were exposed to 
solvent towards the hydrophobic core of the protein. This could further suggest the potency 
of dual targeting in the treatment of Nilotinib resistant CML as compared to regimen with 
Nilotinib alone. Compactness of both systems (singly and dually inhibited) was measured 
by estimating the radius of gyration (RoG) where a high RoG value depicts a reduction or 
loss of structural compactness and vice versa (Lobanov, Bogatyreva, and Galzitskaya, 
2008). The result is shown in Figure 5.8 and reveals that there was a loss of compactness 
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in the structure of Bcr-Abl that was dually inhibited with Nilotinib and ABL001 as 
compared with that which was inhibited with Nilotinib alone. Moreover, the variations in 
structural compactness among the two systems could be relative to inhibition using single 
and dual inhibitors respectively as shown in other results. 
 
Figure 5.8: RoG plot showing the effect of single (Nilotinib) and dual (Nilotinib and 
ABL001) inhibition on the compactness of Bcr-Abl structure. 
5.2.4 Systemic induction of inactive C-terminal helix conformation 
Conformational re-orientation of the C-terminal helix is crucial to the regulation of c-Abl 
activity and inactivity during its auto-inhibition, a regulatory mechanism in normal 
conditions. This occurs upon its myristoylation as a result of the binding of myristate to its 
binding pocket, resulting into a ‘bent’ C-terminal helix conformation, a highlight of an 
inactive or auto-inhibited c-Abl kinase 2, 14. Although Bcr-Abl oncogenic fusion protein is 
not myristoylated due to the lack of the first Abl exon 19, it still possess the myristate-
binding pocket. This has been the subject of allosteric targeting in order to mimic auto-
inhibitory type of regulation as it occurs in non-diseased conditions. Trajectory 
visualization revealed inhibition by nilotinib alone gradually assumed a straight C-terminal 
helix conformation (slightly bent at some trajectories as shown in Figure 9) at around 50ns 
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and was steady until the end of the MD simulation. The distinct fluctuations in structure 
was seen in the RMSF plot. However, the bent C-terminal conformation was induced by 
dual inhibition with both Nilotinib and ABL-001. Other than inducing a ‘bend’ in the C-
terminal helix, it appears that allosteric targeting by ABL-001 locked this conformation 
across the 200ns of MD simulation. This reveals the mechanistic effect of allosteric 
targeting in the potency of dual inhibition relative to Bcr-Abl inactivation and ultimately, 
CML treatment. 
 
Figure 5.9: Superimposed single (gold) and dual (blue) targeted Bcr-Abl complex. Inset 
shows the trajectory visualization of the C-terminal helix conformations of the singly 
inhibited Bcr-Abl (Nilotinib alone - Magenta) and the dually inhibited Bcr-Abl (Nilotinib 
and ABL001 - Red) across the MD simulation time.  
5.3. Conclusion 
Advancement in the treatment of CML has been a subject of research due to the emergence 
of acquired resistance to kinase inhibitors due to mutations in the kinase domain of the 
target Bcr-Abl fusion oncoprotein. These inhibitors were designed as competitive 
inhibitors to prevent the binding of ATP to its kinase domain thereby preventing auto-
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phosphorylation, which accounts for its dysregulation in diseased conditions. Examples 
include Imatinib and Nilotinib. Setbacks in CML therapy with kinase inhibitors due to 
resistance and reduction in drug sensitivity led to allosteric targeting with second site 
inhibitors at the myristate-binding pocket in order to mimic the normal auto-inhibitory 
regulatory mechanism. An example of such allosteric inhibitor is ABL001 (Asciminib). 
Moreover, treatment of CML with the combination of both inhibitors has been shown to 
improve outcomes with no recurrence after treatment cessation compared to single agent 
treatment with kinase inhibitors. Since structural re-orientation characterize activation and 
inactivation of Bcr-Abl most importantly the straight and bent C-terminal helix 
conformation. In this study, we provided the structural basis of dual inhibitory mechanisms 
of Nilotinib (kinase inhibitor) and ABL001 (allosteric inhibitor) compared to single agent 
by Nilotinib alone, to support studies wherein combination therapies where used for 
improved treatment outcomes in CML. Our findings agreed with earlier experimental 
studies and revealed that single-agent inhibition with Nilotinib was unable to induce a 
‘bend’ in the C-terminal helix but maintained its characteristic active straight 
conformation. Also, the protein was shown to exhibit high residual fluctuation, flexibility 
and a low stability that characterizes Bcr-Abl active conformation. However, both 
inhibitors induced an overall structural re-orientation in active Bcr-Abl, which increased 
its stability and conferred rigidity; structural attributes of inactive fusion Bcr-Abl 
oncoproteins. Also, dual inhibition reduced the residual side chains exposed to solvent as 
revealed by surface analysis indicative of protein folding, while single agent inhibition by 
Nilotinib had a higher exposed surface indicative of an unfolded or misfolded protein 
which has been experimentally shown to characterize its activity. Taken together, in 
agreement with previous experimental studies, therapies with allosteric combined with 
catalytic inhibitors possess a great propensity for inactivating Bcr-Abl and ultimately 
improved outcomes in the treatment of CML with acquired resistance to single-agent 
kinase inhibitors. This study will provide structural insight into the basis of dual inhibitory 
mechanisms and aid the design and development of more potent allosteric inhibitors to 
enhance inhibitory activities with kinase inhibitors. 
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5.4. Experimental section - Computational Methodology 
5.4.1 System Preparation 
Crystal structure of c-Abl tyrosine kinase was retrieved from RSCB Protein Data Bank 
(PDBID: 1OPK) 2 and was used to obtain the inactive C-terminal helix protein 
conformation while missing residues were added using Modeller 20.  
Further preparation of the retrieved structure involved the removal of co-crystallized 
substrates that are irrelevant to study. Such include myristoyl acid present in the myristoyl 
binding pocket (allosteric site). This model was used because it constitute the kinase, SH2 
and SH3 domains that characterizes Bcr-Abl oncogenic fusion protein unlike in other 
structures which were distinctively crystallized. T334I point mutation was carried out at 
the catalytic site (kinase domain) of the protein complex using UCSF chimera [18] to 
obtain the Nilotinib-resistant mutant. Both inhibitors; Nilotinib (ID: 644214) and ABL001 
(ID: 72165228) were obtained from Pubchem 21. Protein-inhibitor docking was carried 
sequentially at the catalytic and myristic-binding pocket using Autodock Vina 22 to obtain 
the Bcr-Abl-Nilotinib (BN) and ABL-001-Bcr-Abl-Nilotinib (BAN) complexes; both set 
up for molecular dynamics simulations. Molecular docking preceded the definition of grid 
boxes around the target sites (active and allosteric) of Bcr-Abl to which the inhibitors were 
docked respectively. System visualization and preparation was carried out using UCSF 
chimera 23. 
5.4.2 Molecular dynamics (MD) simulations 
This was carried out on the systems with the GPU version of AMBER 14 with an integrated 
SANDER module 24. This followed a standard simulation protocol, which has been 
previously adopted in our previous studies 25, 26 and enumerated as follows. 
Parameterization of the inhibitors was carried out using the ANTECHAMBER module 
wherein atomic partial charges (Gasteiger – gaff, using the bcc charge scheme) were 
generated 27 while the ff99SB AMBER force field was used to parameterize the proteins. 
Using the LEAP module, hydrogen atoms were added and system neutralized by the 
addition of counter ions, thereby generating ligand, protein and complex topologies and 
parameter files. The systems were explicitly solvated with water using the TIP3P 
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orthorhombic box size of 10Å, which enclosed all atoms of the protein 24. Prior to running 
the LEAP module, the pdb4amber script was executed to protonate the histidine residues 
at a constant pH (cpH). This was employed to automatically modify the protein system for 
use with tleap (Case et al. 2005). Both complexes were minimized initially for 2000 
minimization steps applying a restraint potential of 500kcal/mol and then fully minimized 
for another 1000 steps of steepest descent without restrain. This was followed by gradual 
heating the system with a temperature range of 0-300k for 50ps after which the system was 
equilibrated for 500ps and the temperature and pressure kept constant at 300k and 1bar 
respectively using the Berendsen barostat 28. Without restraints, 200ns MD simulation was 
initiated using a time step of 1fs and coordinates saved at 1ps interval followed by 
subsequent analysis of trajectories using the integrated PTRJ and CPPTRAJ module 29. 
Visualization of the complexes and data plots were carried out using the graphical user 
interface of UCSF chimera 23 and Microcal Origin analytical software 30. 
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The constitutive Bcr-Abl active protein fusion has been identified as the main cause of 
chronic myeloid leukemia (CML).  The emergence of T334I, and D381N point mutations 
in Bcr-Abl confer drug resistance. A recent experimental study shows a synergistic effect 
in supressing this resistance when Nilotinib and ABL001 are co-administered to target both 
the catalytic and allosteric binding site of Bcr-Abl protein, respectively. However, the 
structural mechanism by which this synergistic effect occurs have not been clearly 
elucidated. To obtain insight into the observed synergistic effect, molecular dynamics 
simulations have been employed to investigate the inhibitory mechanism as well as the 
structural dynamics that characterize this effect. Structural dynamic analyses indicate that 
the synergistic binding effect results in a more compact and stable protein conformation. 
In addition, binding free energy calculation suggests a dominant energy effect of nilotinib 
during co-administration.  van der Waals energy interactions was observed to be the main 
energy component driving this synergistic effect. Furthermore, per-residue energy 
decomposition analyses identified Glu481, Ser453, Ala452, Tyr454, Phe401, Asp400, 
Met337, Phe336, Ile334, And Val275 as key residues that contribute largely to the 
synergistic effect. The findings highlighted in this study provide molecular understanding 
of the dynamics and mechanisms that mediate the synergistic inhibition in Bcr-Abl protein 
in chronic myeloid leukemia treatment.  










Chronic myeloid leukemia (CML) is a rare hematopoietic stem cell disorder categorized 
by an acquired balanced chromosomal translocation, which gives rise to a constitutively 
active tyrosine kinase (Bcr-Abl) [1, 2]. Chronic myeloid leukemia pathogenesis involves 
the fusion of the breakpoint cluster region (Bcr) gene on chromosome 22 with the Abelson 
murine leukemia (Abl1) gene on chromosome 9 resulting in the expression of Bcr-Abl 
oncoprotein [3]. This fusion is defined as the Philadelphia chromosome positive (Ph+) , and 
is characterized by a reciprocal translocation between chromosomes 9 and 22, 
t(9;22)(q34;q11) [4]. Bcr-Abl oncoprotein is found exclusively in the cytoplasm of the cell  
and when contrasted with typical ABL, shows deregulated tyrosine kinase action [5, 6] 
thereby clarifying Bcr-Abl role in leukemia. Chronic myeloid leukemia (CML) accounts 
for about 15% of newly diagnosed leukemia cases in adults [7] In CML, immature white 
blood cells are gradually produced crowding in the bone marrow thereby interfering with 
normal blood cell production. Further progression of the disease leads to the shortage of 
red blood cells and platelets, causing anemia, bruising and/or bleeding [8].  
The Bcr-Abl  protein comprises of some domains from both BCR and ABL1 [9]. The BCR 
domains mainly include an N-terminal coiled-coil domain and a Serine/Threonine Kinase 
domain. The ABL1 domains consist of an N-Terminal cap that plays a significant role in 
the regulation of kinase activity, the three Src homology domains (SH3, SH2 and 
SH1/tyrosine kinase domain), and the C-terminal actin-binding domain (Figure 6.1). The 
structural fold of ABL1 kinase forms the catalytic domain containing both N and C-
terminal lobes linked by a short flexible chain referred to as the hinge regions. The cleft 
formed between the two lobes forms the adenosine triphosphate (ATP)-binding site, which 
includes the phosphate binding loop or P-loop [10]. The N- and C- lobes contribute 
conserved residues essential for the catalytic transfer of γ-phosphate from ATP onto the 
tyrosine residue in the substrate protein. The relative positions of the two lobes and the 
active site conserved residues coordinate catalytic reactions and dynamic interchanges 
between active and inactive conformation of the kinase domain. Since most kinases adopt 
similar active conformations, the inactive conformations of the kinase domains are 





Figure 6.1. The 3-D crystal structure of the Abl kinase protein (PDB code: 5MO4). The 
SH3, SH2 and SH1/kinase domains are shown in green, red and yellow, respectively. 
The discovery of Bcr–Abl as a requirement in CML pathogenesis, and the imperative role 
of ABL tyrosine-kinase activity for Bcr–Abl mediated transformation, made ABL kinase 
an attractive therapeutic target in CML interventions [4]. This has resulted in a substantial 
transformation in the therapeutic landscape of CML with the development of tyrosine 
kinase inhibitors (TKIs) that potently inhibit the interaction of Bcr-Abl and ATP. This 
approach has resulted in a 10-year survival rate improvement from about 20% to 80%- 
90% [7, 15]. 
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 Most of the developed Bcr-Abl small-molecule inhibitors are ATP competitive inhibitors 
which occupy the ATP-binding site [16]. However, the ATP-binding site is highly prone 
to mutations. Interestingly, more than 50 different point mutations have been recognized 
in imatinib–resistant patients [17]. Mutations at the gatekeeper are considered the most 
recalcitrant mutations. Asciminib (ABL001) (Figure 6.2) is a highly allosteric selective 
non-ATP competitive inhibitor of oncogenic Bcr-Abl activity [dissociation constant 
(Kd) = 0.5–0.8 nM] recently discovered [18]. ABL001 binds to the myristoyl binding 
pocket at the N-terminus of ABL1 inducing a conformational change that disables the 
protein’s active site, thus, inducing an inactive C-terminal helix conformation [18, 19]. 
Recently, mono therapeutic treatment using ABL001 had led to tumor regression in mice 
xenografted with KCL22 CML cell line. Despite the regression, all of the tumors eventually 
recurred [20–22]. Although this drug has been established to inhibit the Bcr-Abl protein in 
multiple studies [23], there are also numerous investigations on ABL001-resistance 
susceptibility in multiple CML cell lines [19, 21, 24].  
Imatinib mesylate (IM, STI-571 or Gleevec) has been previously reported to competitively 
bind to the ATP active site, thus leading to a loss in Bcr-Abl activity and eventual 
suppression of CML [25]. Nilotinib (AMN-107, Tasigna) is structurally like imatinib but 
with molecular alterations that provide higher affinity towards Bcr-Abl (Figure 6.2). 
Nilotinib is 10-50-fold more potent than imatinib against ABL and shows higher efficacy 
against imatinib-resistant chronic myelogenous leukemia. Nilotinib was approved by FDA 
as a drug of choice for the treatment of patients resistant to imatinib or in an advanced stage 







Figure 6.2. 2D structure of Nilotinib and ABL001 
 
Combination therapy involving both catalytic and allosteric site inhibitors have been shown 
to improve the outcome of CML treatment  and overcoming resistance [20, 21] (Figure 
6.3). Wylie et al (2017) reported conclusive experimental evidence that co-administration 
of Nilotinib and ABL001 bound at both catalytic, and allosteric site respectively suppresses 
the emergency of T334I and D381N resistance [19]. With the availability of drugs for both 
allosteric and active site, obtaining insights into the structural basis of potential dual 
inhibition is therefore imperative. This will enhance our understanding of the effectiveness 







Figure 6.3. Schematic diagram showing the structural effects of single-agents and dual 
inhibition on Bcr-Abl protein complex relative to its activation and inactivation 
conformation. 
In this study, we explored the synergistic therapeutic effect of Bcr-Abl co-inhibition, 
investigated the underlying structural dynamics and inhibitory mechanisms of Nilotinib 
and ABL001 combination therapy to overcome T334I, and D382N resistance. We utilized 
a wide range of in silico approaches to define and compare Bcr-Abl’s structural dynamics 
and binding energy characteristics when jointly inhibited by Nilotinib and ABL001 
compared with the effect of each drug alone. The joint blockade of Bcr-Abl by Nilotinib 
and ABL-001 renders a synergistic effect on Bcr-Abl by inducing a more stable and 
compact protein conformation. The binding energy analysis showed that the joint effect of 
the two drugs was much better when combined compared with the binding effects of each 
drug alone. Our results provide a rational basis for the combination therapy using both 
inhibitors for Bcr-Abl pathway in CML treatment. 
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6.2 Computational Methods 
6.2.1 System Preparation  
Prior to Molecular dynamic (MD) simulations, Bcr-Abl tyrosine kinase in complex with 
ABL001 (asciminib) and Nilotinib was obtained from RSCB Protein Data Bank (PDB 
code: 5MO4) [19]. The Apo structure was manually prepared by deleting the solvent and 
any bound small molecules from the crystal structure. The T334I, and D381Npoint 
mutations were manually introduced with Chimera software. Missing residues were 
modelled using MODELER 9.19 [27] integrated with chimera software [28]. A 200ns MD 
simulations were performed on the four prepared systems (Table 6.1). Protein and ligand 
alterations , as well as visualizations, were conducted in Chimera software [28]. 
Table 1.  The four studied systems and their abbreviations used in the entire paper. 
Studied Systems Abbreviations  Time Step (ns) 
Bcr-Abl Apo BA-Apo 200 
Bcr-Abl in complex with ABL001 alone BA-ABL001 200 
Bcr-Abl in complex with Nilotinib alone BA-Nilotinib 200 
Bcr-Abl in complex with both ABL001 and Nilotinib  BA-Co-inhibition 200 
 
6.2.2 Molecular Dynamic (MD) Simulation 
Molecular dynamic (MD) simulation is an important tool to determine the physical 
movements of atoms and molecules, thus, providing insights on the dynamical evolution 
of biological systems [29]. The MD simulations were carried out on the systems using the 
GPU version of AMBER14 with SANDER module and the FF14SB variant of the AMBER 
force field [30]. Restrained Electrostatic Potential (RESP) [31] and General Amber Force 
Field (GAFF) [32] procedures were used during Antechamber run to complete atomic 
partial charges for the ligands. The receptor and ligands were optimized, and counterions 
added for neutralization using the LEAP module for all studied systems [33]. The systems 
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were completely suspended in an orthorhombic box of TIP3P water molecules, such that 
all atoms were within 10Å of any box edge [34].  
All systems were minimized into two separate minimization stages. An initial partial 
minimization of 2000 steps were achieved with an applied restraint potential of 100 
kcal/mol Å, followed by 1000 steps of full minimization by conjugate gradient algorithm 
without restrain. The system was heated from 0K to 300K for 50ps, such that the system 
maintained a fixed number of atoms and a fixed volume (NVT) with a potential harmonic 
restraint of 10 kcal/mol Å and a collision frequency of 1.0ps-1. The systems were further 
equilibrated at 300k for 500ps in the isothermal-isobaric ensemble (NPT) at a constant 
pressure of 1bar without constrains using the Berendsen barostat.  
A total of 200ns NTP ensemble MD production was performed for each system. In each 
simulation, SHAKE algorithm was employed to constrict the bonds of hydrogen atoms. 
The time step of each simulation was set to 2fs with a constant pressure of 1 bar maintained 
by the Berendsen barostat, a pressure-coupling constant of 2ps, a temperature of 300K and 
Langevin thermostat with collision frequency of 1.0ps-2. Trajectory files were generated 
and subjected to post-dynamic analysis.  
 
6.2.3 Post-Dynamic Analysis 
The  trajectories generated after MD simulations were each saved every 1ps, followed by 
analysis using the CPPTRAJ [35] module employed in AMBER 14 suit. All plots and 
visualizations were completed using the Origin data analysis tool [36] and Chimera [28] 
respectively.  
 
6.2.4 Binding Free Energy Calculations 
Computing of the binding free energy of small ligand to protein is an important endpoint 
method currently used in computational biophysics [37]. To determine the free binding 
energy of each system, the Molecular Mechanics-Generalized-Born Surface Area method 
(MM-GBSA) procedure in AMBER14 was employed [38]. The explicit solvent employed 
in the MD simulation was discarded and replaced with a dielectric continuum [39]. The 
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changes (∆) in each term between complex state and unbound state were calculated for the 
total relative binding free energy [39]. Molecular mechanics force fields were then 
employed to calculate energy contributions from the atomic coordinates of the enzyme, 
ligands and the complex in a gas phase [39]. This technique was used to calculate the 
binding free energy of ABL001, Nilotinib in all systems.  
Binding free energy was averaged over 2000 snapshots extracted from the entire 200ns 
trajectory at an interval of 100. The computing of the binding free energy (ΔG) for each 
molecular species (complex, ligand,and receptor) can be represented as: 
∆Gbind = Gcomplex − Greceptor − Gligand                                         (1) 
∆Gbind = Egas + Gsol − TS                                                                  (2) 
Egas = Eint + Evdw + Eele                                                                   (3) 
Gsol = GGB + GSA                                                                                   (4) 
GSA = γSASA                                                                                           (5) 
 
The term Egas, Eint, Eele, and Evdw symbolize the gas-phase energy, internal energy, Coulomb 
energy, and van der Waals energy respectively. The Egas was directly assessed from the 
FF14SB force field terms. Solvation free energy (Gsol), was assessed from the energy 
involvement from the polar states (GGB), and non-polar states (G). The non-polar solvation 
energy (GSA), was determined from the solvent accessible surface area (SASA), using a 
radius of 1.4 Å, whereas the polar solvation (GGB) contribution assessed by solving the GB 
equation. S and T symbolize the total entropy of the solute and temperature respectively. 
 
6.2.5 Per-Residue Free Energy Decomposition Analysis 
To further identify key active site residues responsible for inhibitor recognition, the 
computed total binding free energy was decomposed to each residue. The binding 
interactions between each residue and the inhibitor were calculated using the MM-GBSA 
per-residue decomposition process in AMBER14.  
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6.3 Results and Discussion  
6.3.1 Overall Structural Stability and Dynamics of the simulated systems  
The stability of the simulated systems was observed by measuring the root mean square 
deviation (RMSD) from the crystallographic structure. The average RMSD C-α atoms of 
the trajectories for all the systems demonstrate that equilibration was achieved after 20ns 
(Figure 6.4a). The recorded average RMSD values for the entire frames of the systems 
were 2.95Å, 2.50Å, 2.28Å, 1.96Å for BA-Apo, BA-Nilotinib, BA-ABL001, and BA-Co-
inhibition respectively. These results show that the co-inhibition of Bcr-Abl by ABL001 
and Nilotinib induces a more stable protein conformation than when ABL001 or Nilotinib 
binds alone.   
Furthermore, to compare the amino acid residue flexibility upon ligand binding, the root 
mean square fluctuation (RMSF) of the protein backbone was measured over 200ns to 
observe inhibitor binding effects towards Bcr-Abl protein structural dynamics. The 
computed average atomic fluctuations for BA-Apo, BA-Nilotinib, BA-ABL001, and BA-
Co-inhibition were 1.22Å, 1.14Å, 1.38Å, and 1.00Å, respectively (Figure 6.4b). These 
results indicate a lower residue fluctuation during BCL-ABL co-inhibition, suggesting that 
the co-binding of ABL001and Nilotinib decreases the overall protein flexibility compared 
to when ABL001 or Nilotinib binds alone to Bcr-Abl.  
To observe the overall Bcr-Abl protein compactness upon ligand binding, the radius of 
gyration (ROG) was computed by measuring the mass-weighted root mean square distance  
of a collection of atoms from the center of mass of complex during the MD simulations 
[40, 41]. The average ROG values are 23.78Å, 23.71Å, 24.03Å and 23.54Å for BA-Apo, 
BA-Nilotinib, BA-ABL001, and BA-Co-inhibition respectively (Figure 6.4c). The 
observed lower ROG value for co-inhibition of Bcr-Abl by ABL001 and Nilotinib 
compared with Bcr-Abl single drug inhibition by ABL001 or Nilotinib only, reflects a 
similar pattern as seen in the RMSF and RMSD values. The observed pattern suggests that 
the co-inhibition of Bcr-Abl by ABL001 and Nilotinib results in a more rigid stable protein 
structure than when ABL001 or Nilotinib binds alone, which results in improved binding 
energy as evidenced by the binding energy results (Table 6.2). 
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To further gain insight on how the protein surface interacts with solvent molecules and to 
obtain insight into the relation of the compactness of the protein hydrophobic core, the 
solvent accessible surface area (SASA) of the protein upon ligand binding was computed 
(Figure 6.4d).  
This was accomplished by measuring the surface area of the protein visible to solvent 
across the 200ns MD simulation, which is essential for biomolecular stability [42]. The 
overall SASA indicates that co-inhibition of Bcr-Abl by ABL001 and Nilotinib less expose 
the protein surface to solvent molecules compared to mono-therapeutic inhibition. The 
computed average SASA values for BA-Apo, BA-Nilotinib, BA-ABL001, and BA-Co-
inhibition systems were 20420.93A2, 19912.11A2, 20053.69A2, and 19526.81A2 
respectively. The SASA results together with the observations from RSMD, RMSF and 
ROG calculations further confirms that the co-administration of ABL001 and Nilotinib 




Figure 6.4. (a) RMSD of Cα atoms of the protein backbone atoms (b) RMSF of each 
residue of the protein backbone Cα atoms (c) Radius of Gyration (ROG) of Cα atoms of 
protein residues, and (d) Solvent accessible surface area (SASA) of the backbone atoms 
relative to the starting minimized over 200ns for BA-Apo, BA-Nilotinib, BA-ABL001, and 
BA-Co-inhibition systems. 
 
6.3.2 Mechanism of binding interactions based on Binding Free Energy Calculation 
The total binding free energy was calculated to gain insight into the binding energetics of 
ABL001 and Nilotinib when each bind alone and when in co-inhibition to Bcr-Abl. The 
MM-GBSA program in AMBER14 was used in calculating the binding free energies by 
extracting snapshots from the trajectories of the compounds.  
As can be seen in Table 6.2, the difference in binding energy of Nilotinib when bound 
alone (-62.77 kcal/mol) and when bound in a complex with ABL001 (-67.51 kcal/mol) was 
-4.74 kcal/mol. The same is true for ABL001 with a binding free energy difference of -
1.85 kcal/mol when bound alone (-40.97 kcal/mol) and when bound in a complex with 
Nilotinib (-42.82 kcal/mol). This indicates a more favorable binding of Nilotinib and 
ABL001when bound in a complex with each other than when each bound alone. The 
computed binding energies correlate well with the experimental IC50 reported values [20, 
21].  
Table 2. Summary of binding free energy components calculated for ABL001 and 
Nilotinib when each bound alone and when in co-inhibition with each other to Bcr-Abl 
systems. All values are given in kcal/mol. Standard deviation given by σ. 
 
Compounds 
Individual binding Co-inhibition of inhibitors 
ABL001 Nilotinib ABL001 Nilotinib 
 Mean σ Mean σ Mean σ Mean σ 
ΔEvdW -49.30 0.05 -70.87 0.04 -48.80 0.18 -74.94 0.20 
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ΔEelec -20.44 0.12 -28.72 0.06 -30.96 0.49 -29.85 0.38 
ΔGgas -69.74 0.14 -99.59 0.07 -79.77 0.50 -104.79 0.41 
ΔGsolv 28.77 0.10 36.82 0.05 36.94 0.38 37.28 0.30 
ΔGbind -40.97 0.07 -62.77 0.05 -42.82 0.21 -67.51 0.25 
 
The MM-GBSA method further allows the decomposition of the total binding free energy 
into the individual contributing energy components, thus providing a detailed 
understanding of the complex binding process. The nonpolar solvation and van der Waals 
interaction energies are observed in all the systems to be responsible for favorable binding 
free energies whereas polar solvation energy terms contribute unfavorably to the binding 
of the inhibitors. The thermodynamic energy contribution of Nilotinib to the total binding 
free energy of the complex surmounts to the stability of ABL001 in the allosteric binding 
pocket and thus the stability of the complex during the simulation.  
6.3.3 Identification of the key residues responsible for inhibitor binding 
To identify the key active site residues involved in the co-inhibition process, the total 
binding free energy of ABL001 and Nilotinib toward Bcr-Abl protein was further 
decomposed into the contribution of each active site residue. The residue interaction energy 
information is shown in Figure 6.5. As can be observed from Figure 6.5a, the major 
favourable energy contributions to ABL001 binding predominately originate from residues 
GLU481 (-2.20 kcal/mol), SER453 (-2.11 kcal/mol), ALA452 (-2.23 kcal/mol), and 
TYR454 (-1.54 kcal/mol) whereas in Figure 6.5b residues PHE401 (-3.13 kcal/mol), 
ASP400 (-1.79 kcal/mol), MET377 (-1.66 kcal/mol), PHE336 (-2.20kcal/mol), ILE334 (-
2.5kcal/mol), and VAL275 (-1.77kcal/mol) largely contribute to Nilotinib binding with 
binding energy contributions ΔGbind  > -1.5 kcal/mol.  
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Figure 6.5. Per-residue decomposition plot showing the energy contributions of the most 
interacting residues at (a) the allosteric binding site with ABL001 and (b) the catalytic 
active site with Nilotinib.   
 
6.3.4 Bcr-Abl Co-Inhibition Interactions and Ligand Binding Mode Analysis 
Figure 6.6 illustrates that the catalytic site residues Asp400, and Phe401 form a stable 
hydrogen bond with the hydroxyl group of Nilotinib whereas Met377 forms a hydrogen 
bond with the amino group of pyrimidine ring of Nilotinib. The amino group of ABL001 
donates a hydrogen bond to residue Glu399 at the allosteric site via its terminal oxygen 
atom with a negatively binding of -2.003 kcal/mol, indicating its importance for binding. 
It is worth to note that highly electrostatic fluorine molecules were found at the base of the 
hydrophobic pocket in both the catalytic and allosteric sites.  
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Figure 6.6:   The key interactions between the catalytic active site and allosteric active site 
residues of Bcr-Abl with ABL001 (A) and Nilotinib (B). 
6.4 Conclusion 
In this study, comparative MD simulation and binding free energy analysis were employed 
to investigate the co-inhibitory mechanism of Nilotinib and ABL001 in the presence and 
absence of each other against Bcr-Abl. Recent experimental evidence shows that co-
administration of Nilotinib and ABL001 bound at both catalytic, and allosteric site 
respectively suppresses the emergency of T334I, and D381N resistance. To this end, we 
investigated the inhibitory mechanism and structural dynamic features that characterize 
this synergistic co-inhibition. Results from this study demonstrated that the co-inhibition 
of Bcr-Abl system induced a more stable, compact protein structure when compared to 
systems in which ABL001 or Nilotinib binds alone. The calculated binding free energy of 
ABL001 or Nilotinib during co-inhibition was higher compared to when each bound alone. 
The binding free energy component analysis suggests that the major energy component 
driving this synergistic effect is van der Waals energy component. The decomposition of 
the total energies into individual active site residue contributions revealed that amino acid 
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residues Glu481, Ser453, Ala452, and Tyr454 are important residues that contribute largely 
to the binding of ABL001, whereas Phe401, Asp400, Met377, Phe336, Ile334, and Val275 
are key to the binding of Nilotinib.  
The findings highlighted in this study provide a molecular understanding of the dynamics 
and mechanisms that mediate the synergistic inhibition in Bcr-Abl protein. Our findings 
will further assist in the optimization of the inhibitory activity of these compounds in 
chronic myeloid leukemia treatment. 
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Despite the notable achievement of kinase inhibitors in the treatment of CML patients, 
recent reports suggest a 5–10% clinical relapse due to drug resistance following long-term 
Imatinib therapy. As a result, finding viable therapeutic approaches to fight against 
Imatinib resistance has become extremely important. Over the last few years, significant 
resistance to kinase inhibitors has been revealed in many approaches, however researchers 
continue to work diligently in the design of therapeutically efficient techniques and 
potential drug molecules that can be co-administered with kinase inhibitors to curb the 
threat of kinase inhibitor resistance.  
The main objectives of this thesis were to reveal molecular insight that may potentially 
eliminate the emergence of resistance to Nilotinib ( kinase inhibitor) by the novel ABL001 
(Allosteric inhibitor) co-bound to Bcr-Abl. The study also sought to provide molecular 
understanding between the interplay of a single active site mutation as well as mutations 
in both the catalytic active site and activation loop which are responsible for the emerging 
resistance in Nilotinib amongst single binding of Nilotinib or upon co-binding with 
ABL001 at the allosteric site. 
The results of this work have confirmed the following conclusions: 
1. Dual inhibition with both Nilotinib and ABL001 induced a more stable and 
compact Bcr-Abl than when Bcr-Abl bound to either Nilotinib or ABL0001 alone. 
2. Thermodynamic calculations have shown that ABL001 has greater stability and 
stronger Nilotinib –Bcr-Abl interactions, which was complemented by remarkable 
compactness of binding site residues of Nilotinib and enhanced interactions of van 
der Waals with dual binding.  
3. The calculated binding free energy of Nilotinib in the presence of ABL001 was 
higher as compared to each drug bound individually to Bcr-Abl, possibly 
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explaining the reasons for suppressing the resistance of Nilotinib as previously 
experimentally predicted. 
4. Per-residue energy decomposition analyses identified Glu481, Ser453, Ala452, 
Tyr454, Phe401, Asp400, Met337, Phe336, Ile334, And Val275 as key residues 
that contribute largely to the synergistic effect. 
5. The study also investigated the impact of a mutation at the catalytic site in addition 
to mutations of both catalytic and activation loop of Bcr-Abl revealing that 
Nilotinib binding affinity and H-bond interactions were decreased with a resultant 
induced structural rearrangement around the mutant sites in Bcr-Abl when either 
Nilotinib or ABL001 is bound.  
6. Dual binding has shown stronger bound to Bcr-Abl compared to monotherapy by 
either Nilotinib or ABL001 amidst the mutations. Results are compatible with the 
previous report of the dramatic impact of the mutation on the attachment of 
Nilotinib to Bcr-Abl, while also conferring with the experimental prediction of the 
suppression of Nilotinib resistance upon dual binding.  
Overall, this study has provided essential conformational and structural molecular insights 
into the design and development of new Bcr-Abl inhibitors through molecular modeling 
and CADD.  
7.2 Future Perspectives 
Using computational tools, the studies reported in this thesis complemented and justified 
previously reported experimental findings, providing consistent molecular insights which 
can be utilized in future studies. Computational perspective presented in these studies 
opened up the scope for future studies, which can serve as the basis for future research. 
1. Findings from this thesis support that dual binding with Nilotinib and ABL001 on Bcr-
Abl suppresses the emergence of either Nilotinib or ABL001 resistance as previously 
predicted experimentally. Further research could still, however, be carried out to provide 
potential pharmacophoric features in the design and development of new small molecules 
inhibitors that can singly target Bcr-Abl to suppress ATP kinase inhibitor resistance. Single 
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acting drugs will reduce the risk of toxicity and will be relatively less expensive than the 
co-administration of two separate drugs. 
2-  To additionally examine the validity of the simulation and parameters proposed for the 
expressive the system studied, the simulation could be performed in longer periods of 
molecular dynamic simulations for each system. A longer system run can be used to 
evaluate parameters proposed and to further understand the impact of co-binding Nilotinib 
and ABL001 on the emergence of either Nilotinib or ABL001 resistance as well the 
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